dho personal page - To The Moon

dho

dho

No personal profile

105Follow

9Followers

0Topic

0Badge

2022-03-11

So sad

Cathie Wood's Ark Is Now Completely Out Of Palantir — Selling Over 30 Million Shares In 1 Month

2021-09-20

Expected

FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations

2021-09-16

It's not a vaccine!

Moderna says COVID-19 vaccine protection wanes, makes case for booster

2021-09-15

Hold hold hold

Apple's new iPhone 13 touts faster 5G, sharper cameras to spur trade-ins

2021-09-12

Evil

Sorry, the original content has been removed

2021-09-07

House always wins

Sorry, the original content has been removed

2021-09-06

How

Why Are United Microelectronics Shares Trading Higher Today?

2021-09-05

Great

@老虎专刊:【老虎週刊】老虎社區一週十大精華文章

2021-09-01

Only way is up

Sorry, the original content has been removed

2021-08-28

Hedging

Crypto stocks surged in morning trading

2021-08-27

Stronger app store, more iPhone sales

Apple Settlement Lets App Makers Advertise Outside Payments

2021-08-27

So?

Snowflake: Why Jim Cramer Thinks Every Fortune 500 Company Will Be a Customer

2021-08-25

Going places

Sorry, the original content has been removed

2021-08-24

Hit 2000!!!!

Gold hovers above $1,800 as early taper expectations cool

2021-08-22

Noooooo

Sorry, the original content has been removed

2021-08-20

Buy?

Spotify announces $1B share repurchase program

2021-08-19

Wats new

Stocks End the Day in an Ugly Way After Fed Minutes Show Taper Talk Is Serious

2021-08-17

Buy this dip

Sorry, the original content has been removed

2021-08-17

Boom

Six hurt in Tesla crash in British school car park -Telegraph

2021-08-13

Go go go

Clover Health, Palantir, SoFi, Wish, Disney And More — Stocks Buzzing On WallStreeBets Today

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3571475992036725,"uuid":"3571475992036725","gmtCreate":1608381968434,"gmtModify":1706620737998,"name":"dho","pinyin":"dho","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":105,"tweetSize":68,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9036084932,"gmtCreate":1646951224942,"gmtModify":1676534179630,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"So sad","listText":"So sad","text":"So sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9036084932","repostId":"1133495712","repostType":4,"repost":{"id":"1133495712","pubTimestamp":1646917591,"share":"https://www.laohu8.com/m/news/1133495712?lang=&edition=full","pubTime":"2022-03-10 21:06","market":"us","language":"en","title":"Cathie Wood's Ark Is Now Completely Out Of Palantir — Selling Over 30 Million Shares In 1 Month","url":"https://stock-news.laohu8.com/highlight/detail?id=1133495712","media":"benzinga","summary":"Cathie Wood-led Ark Investment Management has shed all its holdings in Peter Thiel-backed Palantir T","content":"<html><head></head><body><p>Cathie Wood-led Ark Investment Management has shed all its holdings in Peter Thiel-backed Palantir Technologies Inc (NYSE: PLTR), marking one of the investment firm&#39;s swiftest exists from a stock it was bullish on just over a month ago.</p><p>Ark Invest on Wednesday sold the remaining five shares it held in Palantir via the Ark Space Exploration &amp; Innovation ETF (BATS: ARKX), daily trade data from the investment firm showed.</p><p>For perspective, Ark Invest at the start of February held over 30 million shares, in the data analytics company known for its work with government agencies.</p><p>The popular investment firm, known for holding bets in Tesla Inc (NASDAQ: TSLA) and Coinbase Global Inc (NASDAQ: COIN), shed nearly all of its Palantir exposure in about 13 trades.</p><p>Ark Invest had been piling up Palantir stock for months prior to the selloff that began on Feb. 1, when it sold 3.2 million shares in a single trade.</p><p>It stepped up liquidating efforts after the company reported fourth-quarter earnings of two cents per share, below analyst expectations, sending its shares down 16%.</p><p>“We had some concerns about their (Palantir) competitive positioning within the government space and we had better risk money elsewhere,” Brett Winton, director of Research at Ark Invest, had said in an interview on a YouTube channel earlier this month.</p><p>“It&#39;s an interesting company .. the technology is super interesting and we&#39;re very bullish on AI generally. The marginal competitive weakness on the government side just left us with other places to go.”</p><p>Palantir stock closed 5.5% higher at $11.6 a share on Wednesday. The stock is down 37% year-to-date.</p><p></p><p></p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood's Ark Is Now Completely Out Of Palantir — Selling Over 30 Million Shares In 1 Month</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood's Ark Is Now Completely Out Of Palantir — Selling Over 30 Million Shares In 1 Month\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-10 21:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/22/03/26073561/cathie-woods-ark-is-now-completely-out-of-palantir-selling-over-30-million-shares-in-1-month><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cathie Wood-led Ark Investment Management has shed all its holdings in Peter Thiel-backed Palantir Technologies Inc (NYSE: PLTR), marking one of the investment firm's swiftest exists from a stock it ...</p>\n\n<a href=\"https://www.benzinga.com/news/22/03/26073561/cathie-woods-ark-is-now-completely-out-of-palantir-selling-over-30-million-shares-in-1-month\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","PLTR":"Palantir Technologies Inc."},"source_url":"https://www.benzinga.com/news/22/03/26073561/cathie-woods-ark-is-now-completely-out-of-palantir-selling-over-30-million-shares-in-1-month","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133495712","content_text":"Cathie Wood-led Ark Investment Management has shed all its holdings in Peter Thiel-backed Palantir Technologies Inc (NYSE: PLTR), marking one of the investment firm's swiftest exists from a stock it was bullish on just over a month ago.Ark Invest on Wednesday sold the remaining five shares it held in Palantir via the Ark Space Exploration & Innovation ETF (BATS: ARKX), daily trade data from the investment firm showed.For perspective, Ark Invest at the start of February held over 30 million shares, in the data analytics company known for its work with government agencies.The popular investment firm, known for holding bets in Tesla Inc (NASDAQ: TSLA) and Coinbase Global Inc (NASDAQ: COIN), shed nearly all of its Palantir exposure in about 13 trades.Ark Invest had been piling up Palantir stock for months prior to the selloff that began on Feb. 1, when it sold 3.2 million shares in a single trade.It stepped up liquidating efforts after the company reported fourth-quarter earnings of two cents per share, below analyst expectations, sending its shares down 16%.“We had some concerns about their (Palantir) competitive positioning within the government space and we had better risk money elsewhere,” Brett Winton, director of Research at Ark Invest, had said in an interview on a YouTube channel earlier this month.“It's an interesting company .. the technology is super interesting and we're very bullish on AI generally. The marginal competitive weakness on the government side just left us with other places to go.”Palantir stock closed 5.5% higher at $11.6 a share on Wednesday. The stock is down 37% year-to-date.","news_type":1},"isVote":1,"tweetType":1,"viewCount":293,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887467690,"gmtCreate":1632094713010,"gmtModify":1676530697737,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Expected","listText":"Expected","text":"Expected","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887467690","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","pubTimestamp":1631950800,"share":"https://www.laohu8.com/m/news/2168957763?lang=&edition=full","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885078183,"gmtCreate":1631748783442,"gmtModify":1676530622872,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"It's not a vaccine!&nbsp;","listText":"It's not a vaccine!&nbsp;","text":"It's not a vaccine!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885078183","repostId":"2167059010","repostType":4,"repost":{"id":"2167059010","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631748268,"share":"https://www.laohu8.com/m/news/2167059010?lang=&edition=full","pubTime":"2021-09-16 07:24","market":"us","language":"en","title":"Moderna says COVID-19 vaccine protection wanes, makes case for booster","url":"https://stock-news.laohu8.com/highlight/detail?id=2167059010","media":"Reuters","summary":"CHICAGO, Sept 15 (Reuters) - New data from Moderna Inc's large COVID-19 vaccine trial shows that the","content":"<p>CHICAGO, Sept 15 (Reuters) - New data from Moderna Inc's&nbsp;large COVID-19 vaccine trial shows that the protection it offers wanes over time, supporting the case for booster doses, the company said in a news release on Wednesday.</p>\n<p>\"This is only <a href=\"https://laohu8.com/S/AONE.U\">one</a> estimate, but we do believe this means as you look toward the fall and winter, at minimum we expect the estimated impact of waning immunity would be 600,000 additional cases of COVID-19,\" Moderna President Stephen Hoge said on a conference call with investors.</p>\n<p>Hoge did not project how many of the cases would be severe, but said some would require hospitalization.</p>\n<p>The data stands in stark contrast with data from several recent studies that suggested Moderna's vaccine protection lasts longer than a similar shot from Pfizer Inc and German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> .</p>\n<p>Experts said the difference is likely due to Moderna's higher dose of messenger RNA (mRNA) and the slightly longer interval between the first and second shots.</p>\n<p>Both vaccines proved to be exceedingly effective at preventing illness in their large Phase III studies.</p>\n<p>Wednesday's analysis, however, showed higher rates of infection among people vaccinated roughly 13 months ago compared with those vaccinated roughly eight months ago. The study period was from July-August, when Delta was the predominant strain. It has yet to undergo peer review.</p>\n<p>Moderna on Sept. 1 submitted its application to the U.S. Food and Drug Administration seeking authorization for a booster shot.</p>\n<p>Hoge said data from its booster studies shows the vaccine could increase neutralizing antibodies to levels even higher than were seen after the second dose.</p>\n<p>\"We believe this will reduce COVID-19 cases,\" he said. \"We also believe that a third dose of mRNA-1273 has a chance of significantly extending immunity throughout much of next year as we attempt to end the pandemic.\"</p>\n<p>Briefing documents from the FDA's analysis of Pfizer's booster application, released earlier on Wednesday, suggest that a key issue the agency will consider is whether vaccine protection is waning</p>\n<p>In its analysis, Moderna compared the vaccine's performance in more than 14,000 volunteers vaccinated between July and October of 2020 with some 11,000 volunteers originally in the placebo group who were offered the shot between December 2020 and March 2022 following its U.S. emergency use authorization.</p>\n<p>In the two-month period from July-August, researchers identified 88 COVID-19 cases among those who got the two shots more recently, compared with 162 cases among those vaccinated last year. Overall, only 19 cases were considered severe, a key benchmark in assessing waning protection.</p>\n<p>Moderna said there was a trend toward a lower rate of severe cases among the more recently vaccinated, although the finding was not statistically significant.</p>\n<p>Data from a separate study presented on Wednesday conducted with Kaiser Permanente Southern California health system, meanwhile, shows that Moderna's vaccine continued to perform well against the Delta variant.</p>\n<p>Researchers compared data on more than 352,000 people who got two doses of the Moderna vaccine with the same number of unvaccinated individuals and found the Moderna vaccine was 87% effective at preventing a COVID-19 diagnosis, and 96% effective at preventing hospitalization.</p>\n<p>Hoge said the vaccine's initial performance is strong, but argued that protection shouldn't be allowed to wane.</p>\n<p>\"The first six months are great, but you can't count on that being stable out to a year and beyond,\" he said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna says COVID-19 vaccine protection wanes, makes case for booster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna says COVID-19 vaccine protection wanes, makes case for booster\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-16 07:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CHICAGO, Sept 15 (Reuters) - New data from Moderna Inc's&nbsp;large COVID-19 vaccine trial shows that the protection it offers wanes over time, supporting the case for booster doses, the company said in a news release on Wednesday.</p>\n<p>\"This is only <a href=\"https://laohu8.com/S/AONE.U\">one</a> estimate, but we do believe this means as you look toward the fall and winter, at minimum we expect the estimated impact of waning immunity would be 600,000 additional cases of COVID-19,\" Moderna President Stephen Hoge said on a conference call with investors.</p>\n<p>Hoge did not project how many of the cases would be severe, but said some would require hospitalization.</p>\n<p>The data stands in stark contrast with data from several recent studies that suggested Moderna's vaccine protection lasts longer than a similar shot from Pfizer Inc and German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> .</p>\n<p>Experts said the difference is likely due to Moderna's higher dose of messenger RNA (mRNA) and the slightly longer interval between the first and second shots.</p>\n<p>Both vaccines proved to be exceedingly effective at preventing illness in their large Phase III studies.</p>\n<p>Wednesday's analysis, however, showed higher rates of infection among people vaccinated roughly 13 months ago compared with those vaccinated roughly eight months ago. The study period was from July-August, when Delta was the predominant strain. It has yet to undergo peer review.</p>\n<p>Moderna on Sept. 1 submitted its application to the U.S. Food and Drug Administration seeking authorization for a booster shot.</p>\n<p>Hoge said data from its booster studies shows the vaccine could increase neutralizing antibodies to levels even higher than were seen after the second dose.</p>\n<p>\"We believe this will reduce COVID-19 cases,\" he said. \"We also believe that a third dose of mRNA-1273 has a chance of significantly extending immunity throughout much of next year as we attempt to end the pandemic.\"</p>\n<p>Briefing documents from the FDA's analysis of Pfizer's booster application, released earlier on Wednesday, suggest that a key issue the agency will consider is whether vaccine protection is waning</p>\n<p>In its analysis, Moderna compared the vaccine's performance in more than 14,000 volunteers vaccinated between July and October of 2020 with some 11,000 volunteers originally in the placebo group who were offered the shot between December 2020 and March 2022 following its U.S. emergency use authorization.</p>\n<p>In the two-month period from July-August, researchers identified 88 COVID-19 cases among those who got the two shots more recently, compared with 162 cases among those vaccinated last year. Overall, only 19 cases were considered severe, a key benchmark in assessing waning protection.</p>\n<p>Moderna said there was a trend toward a lower rate of severe cases among the more recently vaccinated, although the finding was not statistically significant.</p>\n<p>Data from a separate study presented on Wednesday conducted with Kaiser Permanente Southern California health system, meanwhile, shows that Moderna's vaccine continued to perform well against the Delta variant.</p>\n<p>Researchers compared data on more than 352,000 people who got two doses of the Moderna vaccine with the same number of unvaccinated individuals and found the Moderna vaccine was 87% effective at preventing a COVID-19 diagnosis, and 96% effective at preventing hospitalization.</p>\n<p>Hoge said the vaccine's initial performance is strong, but argued that protection shouldn't be allowed to wane.</p>\n<p>\"The first six months are great, but you can't count on that being stable out to a year and beyond,\" he said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167059010","content_text":"CHICAGO, Sept 15 (Reuters) - New data from Moderna Inc's large COVID-19 vaccine trial shows that the protection it offers wanes over time, supporting the case for booster doses, the company said in a news release on Wednesday.\n\"This is only one estimate, but we do believe this means as you look toward the fall and winter, at minimum we expect the estimated impact of waning immunity would be 600,000 additional cases of COVID-19,\" Moderna President Stephen Hoge said on a conference call with investors.\nHoge did not project how many of the cases would be severe, but said some would require hospitalization.\nThe data stands in stark contrast with data from several recent studies that suggested Moderna's vaccine protection lasts longer than a similar shot from Pfizer Inc and German partner BioNTech SE .\nExperts said the difference is likely due to Moderna's higher dose of messenger RNA (mRNA) and the slightly longer interval between the first and second shots.\nBoth vaccines proved to be exceedingly effective at preventing illness in their large Phase III studies.\nWednesday's analysis, however, showed higher rates of infection among people vaccinated roughly 13 months ago compared with those vaccinated roughly eight months ago. The study period was from July-August, when Delta was the predominant strain. It has yet to undergo peer review.\nModerna on Sept. 1 submitted its application to the U.S. Food and Drug Administration seeking authorization for a booster shot.\nHoge said data from its booster studies shows the vaccine could increase neutralizing antibodies to levels even higher than were seen after the second dose.\n\"We believe this will reduce COVID-19 cases,\" he said. \"We also believe that a third dose of mRNA-1273 has a chance of significantly extending immunity throughout much of next year as we attempt to end the pandemic.\"\nBriefing documents from the FDA's analysis of Pfizer's booster application, released earlier on Wednesday, suggest that a key issue the agency will consider is whether vaccine protection is waning\nIn its analysis, Moderna compared the vaccine's performance in more than 14,000 volunteers vaccinated between July and October of 2020 with some 11,000 volunteers originally in the placebo group who were offered the shot between December 2020 and March 2022 following its U.S. emergency use authorization.\nIn the two-month period from July-August, researchers identified 88 COVID-19 cases among those who got the two shots more recently, compared with 162 cases among those vaccinated last year. Overall, only 19 cases were considered severe, a key benchmark in assessing waning protection.\nModerna said there was a trend toward a lower rate of severe cases among the more recently vaccinated, although the finding was not statistically significant.\nData from a separate study presented on Wednesday conducted with Kaiser Permanente Southern California health system, meanwhile, shows that Moderna's vaccine continued to perform well against the Delta variant.\nResearchers compared data on more than 352,000 people who got two doses of the Moderna vaccine with the same number of unvaccinated individuals and found the Moderna vaccine was 87% effective at preventing a COVID-19 diagnosis, and 96% effective at preventing hospitalization.\nHoge said the vaccine's initial performance is strong, but argued that protection shouldn't be allowed to wane.\n\"The first six months are great, but you can't count on that being stable out to a year and beyond,\" he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882355161,"gmtCreate":1631663617553,"gmtModify":1676530601889,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Hold hold hold","listText":"Hold hold hold","text":"Hold hold hold","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/882355161","repostId":"2167568176","repostType":4,"repost":{"id":"2167568176","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631662384,"share":"https://www.laohu8.com/m/news/2167568176?lang=&edition=full","pubTime":"2021-09-15 07:33","market":"us","language":"en","title":"Apple's new iPhone 13 touts faster 5G, sharper cameras to spur trade-ins","url":"https://stock-news.laohu8.com/highlight/detail?id=2167568176","media":"Reuters","summary":"Sept 14 (Reuters) - Apple Inc unveiled the iPhone 13 and a new iPad mini on Tuesday, expanding 5G co","content":"<p>Sept 14 (Reuters) - Apple Inc unveiled the iPhone 13 and a new iPad mini on Tuesday, expanding 5G connectivity and showing off faster chips and sharper cameras without raising the phone's price.</p>\n<p>The Cupertino, California-based company did not announce any blockbuster features or products, but analysts expect customers hanging onto older models like the iPhone X will be eager to upgrade. To encourage trade-ins, participating wireless carriers are offering incentives ahead of the year-end holiday season that to make the new phones free to some customers.</p>\n<p>The iPhone 13&nbsp;will have a new chip called the A15 Bionic that enables features like automatically translating text. The phone also has a better display, longer battery life and a Cinematic mode for automatically changing focus while taking videos. Apple said the iPhone 13 will have custom 5G antennas and radio components for faster speeds and will come in five colors.</p>\n<p>The phone will start at $699, and participating wireless carriers will offer up to $700 off for qualifying trade-ins. The iPhone 13 Pro starts at $999 and the Pro Max starts at $1,099, with trade-in offers of up to $1,000. All three models will be available Sept. 24.</p>\n<p>The prices are unchanged from last year, but some carriers such as AT&amp;T Inc will offer the devices for no additional charge with subsidies of up to $1,000 if customers trade in a previous model and sign up for an installment plan.</p>\n<p>Verizon Communications Inc&nbsp;and <a href=\"https://laohu8.com/S/TMUSR\">T-Mobile US Inc</a>&nbsp;offered similar deals but with slightly lower subsidies up to $700. The biggest subsidies will go to customers who turn in iPhone 11 and iPhone 12 models.</p>\n<p>Ben Bajarin, head of consumer technologies at Creative Strategies, said he expects those aggressive subsides will increase as Apple and carriers try to hold onto customers.</p>\n<p>\"That offer is unique to Apple, and it's a strength they have to keep these sales cycles going for them and for the carriers,\" Bajarin said.</p>\n<p>The iPhone is Apple's most important product, but Apple has rolled out a web of service and other products that are seen as locking customers into a system they enjoy -- and would find expensive to leave.</p>\n<p>The Series 7 smart watch will feature a larger display and faster charging. It will start at $399 and be available later this autumn.</p>\n<p>The company also updated its iPad Mini with 5G connectivity and a reworked design that makes it look like the higher-end iPad Air and Pro models. Bob O'Donnell, head of TECHnalysis Research, said the small tablet was Apple's most surprising announcement and could lure in customers who want a device with 5G that can handle more powerful apps than a phone.</p>\n<p>\"I don't think it replaces any other device, like we've seen Apple try to position some of the bigger iPads as PC replacements,\" O'Donnell said.</p>\n<p>The new iPad Mini's price rose by $100, but it also added new capabilities like compatibility with the company's Apple Pencil and a faster chip than the larger-screened base model iPad, bucking a trend of smaller screens being cheaper. Apple showed the Mini in use by professionals like doctors.</p>\n<p>Apple also updated its base-model iPad with a new camera. The new iPad will start at $329 and the Mini at $499. Both will be available next week.</p>\n<p>Apple shares closed down about 1%, a sharper fall than a slight downturn in broader markets.</p>\n<p>\"It seems like there's nothing really revolutionary announced, but of course, as usual, they announced enough improvements to at least generate some enthusiasm among consumers,\" said Rick Meckler, partner at family investment office Cherry Lane Investments.</p>\n<p>Apple's biggest product launch of the year comes as some of the shine has come off its stock as business practices such as charging software developers commissions on in-app payments have come under regulatory scrutiny.</p>\n<p>Apple shares were up about 11.6% year to date as of Tuesday's close, trailing the Nasdaq Composite Index , which was up 16.7% over the same period.</p>\n<p>Kim Forrest, founder and chief investment officer at Bokeh Capital, said she was not concerned by the lack of splashy, unexpected products, since Apple's upgrades would keep customers. \"I think the consumer, once it gets the Apple chip in its head, it's very hard to dislodge,\" she said.</p>\n<p>The Apple Watch has become a cornerstone of its $30.6 billion accessories segment, which was up 25% in Apple's most recent fiscal year even as its iPhone revenue declined slightly. Analysts widely believe that Apple users who buy more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> product - such as an Apple Watch and iPhone - are more likely to stick with the brand and spend on the company's apps and services.</p>\n<p>Apple focused on fitness features such as improving how the watch tracks bicycling workouts and dust protection for hiking. The watch is paired tightly with Apple Fitness+, a paid service offering guided workouts with Apple instructors. The company added pilates, skiing-oriented workouts and group workouts.</p>\n<p>Shares of exercise bike and online training company Peloton&nbsp;were down about 1.6%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple's new iPhone 13 touts faster 5G, sharper cameras to spur trade-ins</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple's new iPhone 13 touts faster 5G, sharper cameras to spur trade-ins\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-15 07:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sept 14 (Reuters) - Apple Inc unveiled the iPhone 13 and a new iPad mini on Tuesday, expanding 5G connectivity and showing off faster chips and sharper cameras without raising the phone's price.</p>\n<p>The Cupertino, California-based company did not announce any blockbuster features or products, but analysts expect customers hanging onto older models like the iPhone X will be eager to upgrade. To encourage trade-ins, participating wireless carriers are offering incentives ahead of the year-end holiday season that to make the new phones free to some customers.</p>\n<p>The iPhone 13&nbsp;will have a new chip called the A15 Bionic that enables features like automatically translating text. The phone also has a better display, longer battery life and a Cinematic mode for automatically changing focus while taking videos. Apple said the iPhone 13 will have custom 5G antennas and radio components for faster speeds and will come in five colors.</p>\n<p>The phone will start at $699, and participating wireless carriers will offer up to $700 off for qualifying trade-ins. The iPhone 13 Pro starts at $999 and the Pro Max starts at $1,099, with trade-in offers of up to $1,000. All three models will be available Sept. 24.</p>\n<p>The prices are unchanged from last year, but some carriers such as AT&amp;T Inc will offer the devices for no additional charge with subsidies of up to $1,000 if customers trade in a previous model and sign up for an installment plan.</p>\n<p>Verizon Communications Inc&nbsp;and <a href=\"https://laohu8.com/S/TMUSR\">T-Mobile US Inc</a>&nbsp;offered similar deals but with slightly lower subsidies up to $700. The biggest subsidies will go to customers who turn in iPhone 11 and iPhone 12 models.</p>\n<p>Ben Bajarin, head of consumer technologies at Creative Strategies, said he expects those aggressive subsides will increase as Apple and carriers try to hold onto customers.</p>\n<p>\"That offer is unique to Apple, and it's a strength they have to keep these sales cycles going for them and for the carriers,\" Bajarin said.</p>\n<p>The iPhone is Apple's most important product, but Apple has rolled out a web of service and other products that are seen as locking customers into a system they enjoy -- and would find expensive to leave.</p>\n<p>The Series 7 smart watch will feature a larger display and faster charging. It will start at $399 and be available later this autumn.</p>\n<p>The company also updated its iPad Mini with 5G connectivity and a reworked design that makes it look like the higher-end iPad Air and Pro models. Bob O'Donnell, head of TECHnalysis Research, said the small tablet was Apple's most surprising announcement and could lure in customers who want a device with 5G that can handle more powerful apps than a phone.</p>\n<p>\"I don't think it replaces any other device, like we've seen Apple try to position some of the bigger iPads as PC replacements,\" O'Donnell said.</p>\n<p>The new iPad Mini's price rose by $100, but it also added new capabilities like compatibility with the company's Apple Pencil and a faster chip than the larger-screened base model iPad, bucking a trend of smaller screens being cheaper. Apple showed the Mini in use by professionals like doctors.</p>\n<p>Apple also updated its base-model iPad with a new camera. The new iPad will start at $329 and the Mini at $499. Both will be available next week.</p>\n<p>Apple shares closed down about 1%, a sharper fall than a slight downturn in broader markets.</p>\n<p>\"It seems like there's nothing really revolutionary announced, but of course, as usual, they announced enough improvements to at least generate some enthusiasm among consumers,\" said Rick Meckler, partner at family investment office Cherry Lane Investments.</p>\n<p>Apple's biggest product launch of the year comes as some of the shine has come off its stock as business practices such as charging software developers commissions on in-app payments have come under regulatory scrutiny.</p>\n<p>Apple shares were up about 11.6% year to date as of Tuesday's close, trailing the Nasdaq Composite Index , which was up 16.7% over the same period.</p>\n<p>Kim Forrest, founder and chief investment officer at Bokeh Capital, said she was not concerned by the lack of splashy, unexpected products, since Apple's upgrades would keep customers. \"I think the consumer, once it gets the Apple chip in its head, it's very hard to dislodge,\" she said.</p>\n<p>The Apple Watch has become a cornerstone of its $30.6 billion accessories segment, which was up 25% in Apple's most recent fiscal year even as its iPhone revenue declined slightly. Analysts widely believe that Apple users who buy more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> product - such as an Apple Watch and iPhone - are more likely to stick with the brand and spend on the company's apps and services.</p>\n<p>Apple focused on fitness features such as improving how the watch tracks bicycling workouts and dust protection for hiking. The watch is paired tightly with Apple Fitness+, a paid service offering guided workouts with Apple instructors. The company added pilates, skiing-oriented workouts and group workouts.</p>\n<p>Shares of exercise bike and online training company Peloton&nbsp;were down about 1.6%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"T":"美国电话电报","AAPL":"苹果","TMUS":"T-Mobile US Inc","VZ":"威瑞森"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167568176","content_text":"Sept 14 (Reuters) - Apple Inc unveiled the iPhone 13 and a new iPad mini on Tuesday, expanding 5G connectivity and showing off faster chips and sharper cameras without raising the phone's price.\nThe Cupertino, California-based company did not announce any blockbuster features or products, but analysts expect customers hanging onto older models like the iPhone X will be eager to upgrade. To encourage trade-ins, participating wireless carriers are offering incentives ahead of the year-end holiday season that to make the new phones free to some customers.\nThe iPhone 13 will have a new chip called the A15 Bionic that enables features like automatically translating text. The phone also has a better display, longer battery life and a Cinematic mode for automatically changing focus while taking videos. Apple said the iPhone 13 will have custom 5G antennas and radio components for faster speeds and will come in five colors.\nThe phone will start at $699, and participating wireless carriers will offer up to $700 off for qualifying trade-ins. The iPhone 13 Pro starts at $999 and the Pro Max starts at $1,099, with trade-in offers of up to $1,000. All three models will be available Sept. 24.\nThe prices are unchanged from last year, but some carriers such as AT&T Inc will offer the devices for no additional charge with subsidies of up to $1,000 if customers trade in a previous model and sign up for an installment plan.\nVerizon Communications Inc and T-Mobile US Inc offered similar deals but with slightly lower subsidies up to $700. The biggest subsidies will go to customers who turn in iPhone 11 and iPhone 12 models.\nBen Bajarin, head of consumer technologies at Creative Strategies, said he expects those aggressive subsides will increase as Apple and carriers try to hold onto customers.\n\"That offer is unique to Apple, and it's a strength they have to keep these sales cycles going for them and for the carriers,\" Bajarin said.\nThe iPhone is Apple's most important product, but Apple has rolled out a web of service and other products that are seen as locking customers into a system they enjoy -- and would find expensive to leave.\nThe Series 7 smart watch will feature a larger display and faster charging. It will start at $399 and be available later this autumn.\nThe company also updated its iPad Mini with 5G connectivity and a reworked design that makes it look like the higher-end iPad Air and Pro models. Bob O'Donnell, head of TECHnalysis Research, said the small tablet was Apple's most surprising announcement and could lure in customers who want a device with 5G that can handle more powerful apps than a phone.\n\"I don't think it replaces any other device, like we've seen Apple try to position some of the bigger iPads as PC replacements,\" O'Donnell said.\nThe new iPad Mini's price rose by $100, but it also added new capabilities like compatibility with the company's Apple Pencil and a faster chip than the larger-screened base model iPad, bucking a trend of smaller screens being cheaper. Apple showed the Mini in use by professionals like doctors.\nApple also updated its base-model iPad with a new camera. The new iPad will start at $329 and the Mini at $499. Both will be available next week.\nApple shares closed down about 1%, a sharper fall than a slight downturn in broader markets.\n\"It seems like there's nothing really revolutionary announced, but of course, as usual, they announced enough improvements to at least generate some enthusiasm among consumers,\" said Rick Meckler, partner at family investment office Cherry Lane Investments.\nApple's biggest product launch of the year comes as some of the shine has come off its stock as business practices such as charging software developers commissions on in-app payments have come under regulatory scrutiny.\nApple shares were up about 11.6% year to date as of Tuesday's close, trailing the Nasdaq Composite Index , which was up 16.7% over the same period.\nKim Forrest, founder and chief investment officer at Bokeh Capital, said she was not concerned by the lack of splashy, unexpected products, since Apple's upgrades would keep customers. \"I think the consumer, once it gets the Apple chip in its head, it's very hard to dislodge,\" she said.\nThe Apple Watch has become a cornerstone of its $30.6 billion accessories segment, which was up 25% in Apple's most recent fiscal year even as its iPhone revenue declined slightly. Analysts widely believe that Apple users who buy more than one product - such as an Apple Watch and iPhone - are more likely to stick with the brand and spend on the company's apps and services.\nApple focused on fitness features such as improving how the watch tracks bicycling workouts and dust protection for hiking. The watch is paired tightly with Apple Fitness+, a paid service offering guided workouts with Apple instructors. The company added pilates, skiing-oriented workouts and group workouts.\nShares of exercise bike and online training company Peloton were down about 1.6%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":527,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881718670,"gmtCreate":1631405062590,"gmtModify":1676530540668,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Evil","listText":"Evil","text":"Evil","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/881718670","repostId":"2166371940","repostType":4,"isVote":1,"tweetType":1,"viewCount":400,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":817500468,"gmtCreate":1630972845954,"gmtModify":1676530429651,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"House always wins","listText":"House always wins","text":"House always wins","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/817500468","repostId":"1118832287","repostType":4,"isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814462477,"gmtCreate":1630876825699,"gmtModify":1676530407662,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"How","listText":"How","text":"How","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/814462477","repostId":"1168087683","repostType":4,"repost":{"id":"1168087683","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630678318,"share":"https://www.laohu8.com/m/news/1168087683?lang=&edition=full","pubTime":"2021-09-03 22:11","market":"us","language":"en","title":"Why Are United Microelectronics Shares Trading Higher Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1168087683","media":"Tiger Newspress","summary":"United Microelectronics shares surged nearly 6% in early trading.\n\n\nUnited Microelectronics Corp is ","content":"<p>United&nbsp;Microelectronics&nbsp;shares&nbsp;surged&nbsp;nearly&nbsp;6%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/2124600374fa16c7cdaf7835410db05b\" tg-width=\"878\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>United Microelectronics Corp</b>&nbsp;is the third-largest dedicated chip foundry, with a 7% market share in 2020 as per Gartner after&nbsp;<b>Taiwan Semiconductor Manufacturing Co Ltd</b>&nbsp;and GlobalFoundries.</li>\n <li>As per reports, the UMC aims to hike its prices for the second time for its 28-nm technology in quick succession.</li>\n <li>Rival TSM, which decided to keep the 28-nm prices intact,&nbsp;planned a 10% hike&nbsp;for its sub-16nm prices in 2022.</li>\n <li>It seems like an opportune moment to&nbsp;raise the prices&nbsp;considering the demand surge&nbsp;aided chip crisis.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are United Microelectronics Shares Trading Higher Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are United Microelectronics Shares Trading Higher Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-03 22:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>United&nbsp;Microelectronics&nbsp;shares&nbsp;surged&nbsp;nearly&nbsp;6%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/2124600374fa16c7cdaf7835410db05b\" tg-width=\"878\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>United Microelectronics Corp</b>&nbsp;is the third-largest dedicated chip foundry, with a 7% market share in 2020 as per Gartner after&nbsp;<b>Taiwan Semiconductor Manufacturing Co Ltd</b>&nbsp;and GlobalFoundries.</li>\n <li>As per reports, the UMC aims to hike its prices for the second time for its 28-nm technology in quick succession.</li>\n <li>Rival TSM, which decided to keep the 28-nm prices intact,&nbsp;planned a 10% hike&nbsp;for its sub-16nm prices in 2022.</li>\n <li>It seems like an opportune moment to&nbsp;raise the prices&nbsp;considering the demand surge&nbsp;aided chip crisis.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UMC":"联电"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168087683","content_text":"United Microelectronics shares surged nearly 6% in early trading.\n\n\nUnited Microelectronics Corp is the third-largest dedicated chip foundry, with a 7% market share in 2020 as per Gartner after Taiwan Semiconductor Manufacturing Co Ltd and GlobalFoundries.\nAs per reports, the UMC aims to hike its prices for the second time for its 28-nm technology in quick succession.\nRival TSM, which decided to keep the 28-nm prices intact, planned a 10% hike for its sub-16nm prices in 2022.\nIt seems like an opportune moment to raise the prices considering the demand surge aided chip crisis.","news_type":1},"isVote":1,"tweetType":1,"viewCount":315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814510683,"gmtCreate":1630841935342,"gmtModify":1676530404337,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/814510683","repostId":"814882195","repostType":1,"repost":{"id":814882195,"gmtCreate":1630806110311,"gmtModify":1676530397068,"author":{"id":"35433028694349","authorId":"35433028694349","name":"老虎专刊","avatar":"https://static.laohu8.com/e0b93d50cf0df54ce7b1b746f78db36c","crmLevel":1,"crmLevelSwitch":0},"themes":[],"title":"【老虎週刊】老虎社區一週十大精華文章","htmlText":"嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： <a href=\"https://laohu8.com/TW/816814337\" target=\"_blank\">百年老店的Baillie Gifford 爲何能頻繁投中高速增長標的？</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3519157433193136\">@美港股觀察社</a> 特斯拉去年上漲超過8倍，Moderna今年以來上接近4倍，如果去年買特斯拉，今年買Moderna，那簡直不要太high了。不過，還是真的有一家機構踩中這個節奏，這家機構是誰呢？ <a href=\"https://laohu8.com/TW/818191933\" target=\"_blank\">海倫司小酒館憑什麼敢發得這麼貴？</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/279327367386116\">@小斯聊新股</a> 海倫司的發展路徑是：開店——培養客戶羣——打響知名度——開店，聽起來跟瘋狂擴張的奶茶店很像，因此它盈利多少其實並不是很重要。可能是酒館這樣的行業實在是利潤空間潛力很大，因此海倫司儘管走的是低價路線，依然盈利得好好的。這一點，<a target=\"_blank\" href=\"https://laohu8.com/S/LKNCY\">$瑞幸咖啡(LKNCY)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/02150\">$奈雪的茶(02150)$</a> 這樣的國民奶","listText":"嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： <a href=\"https://laohu8.com/TW/816814337\" target=\"_blank\">百年老店的Baillie Gifford 爲何能頻繁投中高速增長標的？</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3519157433193136\">@美港股觀察社</a> 特斯拉去年上漲超過8倍，Moderna今年以來上接近4倍，如果去年買特斯拉，今年買Moderna，那簡直不要太high了。不過，還是真的有一家機構踩中這個節奏，這家機構是誰呢？ <a href=\"https://laohu8.com/TW/818191933\" target=\"_blank\">海倫司小酒館憑什麼敢發得這麼貴？</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/279327367386116\">@小斯聊新股</a> 海倫司的發展路徑是：開店——培養客戶羣——打響知名度——開店，聽起來跟瘋狂擴張的奶茶店很像，因此它盈利多少其實並不是很重要。可能是酒館這樣的行業實在是利潤空間潛力很大，因此海倫司儘管走的是低價路線，依然盈利得好好的。這一點，<a target=\"_blank\" href=\"https://laohu8.com/S/LKNCY\">$瑞幸咖啡(LKNCY)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/02150\">$奈雪的茶(02150)$</a> 這樣的國民奶","text":"嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： 百年老店的Baillie Gifford 爲何能頻繁投中高速增長標的？ 發佈者：@美港股觀察社 特斯拉去年上漲超過8倍，Moderna今年以來上接近4倍，如果去年買特斯拉，今年買Moderna，那簡直不要太high了。不過，還是真的有一家機構踩中這個節奏，這家機構是誰呢？ 海倫司小酒館憑什麼敢發得這麼貴？ 發佈者：@小斯聊新股 海倫司的發展路徑是：開店——培養客戶羣——打響知名度——開店，聽起來跟瘋狂擴張的奶茶店很像，因此它盈利多少其實並不是很重要。可能是酒館這樣的行業實在是利潤空間潛力很大，因此海倫司儘管走的是低價路線，依然盈利得好好的。這一點，$瑞幸咖啡(LKNCY)$ 、$奈雪的茶(02150)$ 這樣的國民奶","images":[{"img":"https://static.tigerbbs.com/4277176bc1e63eea880f31f89bd6c8af","width":"830","height":"566"},{"img":"https://static.tigerbbs.com/e6925f1c638defe87109478a607ed48f","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/5e8c733bc1e6dc8bab9c0b8cb3a900c4","width":"1919","height":"1020"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/814882195","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":9,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816363124,"gmtCreate":1630468122668,"gmtModify":1676530312014,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Only way is up","listText":"Only way is up","text":"Only way is up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816363124","repostId":"2164869989","repostType":4,"isVote":1,"tweetType":1,"viewCount":278,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819715090,"gmtCreate":1630107617810,"gmtModify":1676530224710,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Hedging","listText":"Hedging","text":"Hedging","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819715090","repostId":"1199074003","repostType":4,"repost":{"id":"1199074003","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630077382,"share":"https://www.laohu8.com/m/news/1199074003?lang=&edition=full","pubTime":"2021-08-27 23:16","market":"us","language":"en","title":"Crypto stocks surged in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1199074003","media":"Tiger Newspress","summary":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,","content":"<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks surged in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks surged in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-27 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc.","BTCM":"BIT Mining","BTBT":"Bit Digital, Inc.","NCTY":"第九城市","MARA":"Marathon Digital Holdings Inc","CAN":"嘉楠科技","EBON":"亿邦国际","RIOT":"Riot Platforms","SOS":"SOS Limited","SQ":"Block"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199074003","content_text":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase and Paypal climbed between 1% and 13%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819389724,"gmtCreate":1630034116668,"gmtModify":1676530206438,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Stronger app store, more iPhone sales","listText":"Stronger app store, more iPhone sales","text":"Stronger app store, more iPhone sales","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819389724","repostId":"2162145170","repostType":4,"repost":{"id":"2162145170","pubTimestamp":1630028970,"share":"https://www.laohu8.com/m/news/2162145170?lang=&edition=full","pubTime":"2021-08-27 09:49","market":"us","language":"en","title":"Apple Settlement Lets App Makers Advertise Outside Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2162145170","media":"Bloomberg","summary":"(Bloomberg) -- Apple Inc. settled a wide-ranging class action lawsuit with U.S. app makers Thursday,","content":"<p>(Bloomberg) -- Apple Inc. settled a wide-ranging class action lawsuit with U.S. app makers Thursday, announcing changes to the App Store such as giving developers more flexibility to advertise outside payment methods.</p>\n<p>The settlement will include $100 million worth of payments to app makers ranging from $250 to $30,000 per developer, according to law firm Hagens Berman, which represented plaintiffs who claimed Apple overcharged them fees required for distributing their programs through the iOS App Store. The new advertising policy, meanwhile, will make it easier for developers to promote alternative pricing plans and ways to pay -- without Apple taking a cut.</p>\n<p>Apple has long allowed developers to advertise external payment methods -- such as Netflix Inc. pointing users via email to sign up on its website instead of the app -- but has frowned upon the practice. The new policy ensures Apple can’t ban developers for these communications. It doesn’t, however, let developers advertise outside pricing or payment methods within apps themselves.</p>\n<p>The company is “clarifying that developers can use communications, such as email, to share information about payment methods outside of their iOS app,” Apple said in a statement.</p>\n<p>Critically for Apple, the settlement excludes more significant App Store changes that were sought by some outside developers and legislators. The company is still requiring developers to sell their apps -- as well as in-app items and subscriptions -- using Apple’s payment system, which takes between 15% and 30% in commissions. Apple reduced the cut to 15% for all developers that generate $1 million or less annually last year. On Thursday, it committed to continuing that policy for the next three years.</p>\n<p>The settlement also doesn’t require Apple to allow third-party app stores or the so-called sideloading of software. And the company doesn’t have to further reduce its revenue share. The accord will require approval from Judge Yvonne Gonzalez Rogers, who is overseeing this lawsuit. She is also the judge in Apple’s lawsuit with Epic Games Inc., which has contested the App Store policies as well. It’s unclear if this settlement will affect her opinion in that higher-stakes suit with the maker of Fortnite.</p>\n<p>Apple’s App Store practices have come under increasing scrutiny in recent months, with critics saying the tech giant wields too much power in the industry. U.S. Senators have griped about the “gatekeeper control” that Apple and Google have with their mobile operating systems, forcing the companies to testify before Congress. And South Korea is poised to become the first country to impose curbs on the companies’ app marketplaces.</p>\n<p>Apple’s App Store practices have come under increasing scrutiny in recent months, with critics saying the tech giant wields too much power in the industry. U.S. Senators have griped about the “gatekeeper control” that Apple and Google have with their mobile operating systems and have hauled the companies into congressional hearings. And South Korea is poised to become the first country to impose curbs on the companies’ app marketplaces.</p>\n<p>With Thursday’s agreement, Apple said it would retain recent changes to the App Store search engine for the next three years. “At the request of developers, Apple has agreed that its Search results will continue to be based on objective characteristics like downloads, star ratings, text relevance and user behavior signals,” Apple said.</p>\n<p>The Cupertino, California-based company is also expanding the number of price points developers can offer from fewer than 100 to more than 500, and it will publish an annual App Store transparency report.</p>\n<p>That report “will share meaningful statistics about the app review process, including the number of apps rejected for different reasons, the number of customer and developer accounts deactivated, objective data regarding search queries and results, and the number of apps removed from the App Store,” according to Apple. And the company plans to detail more information about its app review process on its website.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Settlement Lets App Makers Advertise Outside Payments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Settlement Lets App Makers Advertise Outside Payments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 09:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/apple-settlement-lets-app-makers-012730542.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Apple Inc. settled a wide-ranging class action lawsuit with U.S. app makers Thursday, announcing changes to the App Store such as giving developers more flexibility to advertise outside...</p>\n\n<a href=\"https://finance.yahoo.com/news/apple-settlement-lets-app-makers-012730542.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞","GOOGL":"谷歌A","GOOG":"谷歌"},"source_url":"https://finance.yahoo.com/news/apple-settlement-lets-app-makers-012730542.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2162145170","content_text":"(Bloomberg) -- Apple Inc. settled a wide-ranging class action lawsuit with U.S. app makers Thursday, announcing changes to the App Store such as giving developers more flexibility to advertise outside payment methods.\nThe settlement will include $100 million worth of payments to app makers ranging from $250 to $30,000 per developer, according to law firm Hagens Berman, which represented plaintiffs who claimed Apple overcharged them fees required for distributing their programs through the iOS App Store. The new advertising policy, meanwhile, will make it easier for developers to promote alternative pricing plans and ways to pay -- without Apple taking a cut.\nApple has long allowed developers to advertise external payment methods -- such as Netflix Inc. pointing users via email to sign up on its website instead of the app -- but has frowned upon the practice. The new policy ensures Apple can’t ban developers for these communications. It doesn’t, however, let developers advertise outside pricing or payment methods within apps themselves.\nThe company is “clarifying that developers can use communications, such as email, to share information about payment methods outside of their iOS app,” Apple said in a statement.\nCritically for Apple, the settlement excludes more significant App Store changes that were sought by some outside developers and legislators. The company is still requiring developers to sell their apps -- as well as in-app items and subscriptions -- using Apple’s payment system, which takes between 15% and 30% in commissions. Apple reduced the cut to 15% for all developers that generate $1 million or less annually last year. On Thursday, it committed to continuing that policy for the next three years.\nThe settlement also doesn’t require Apple to allow third-party app stores or the so-called sideloading of software. And the company doesn’t have to further reduce its revenue share. The accord will require approval from Judge Yvonne Gonzalez Rogers, who is overseeing this lawsuit. She is also the judge in Apple’s lawsuit with Epic Games Inc., which has contested the App Store policies as well. It’s unclear if this settlement will affect her opinion in that higher-stakes suit with the maker of Fortnite.\nApple’s App Store practices have come under increasing scrutiny in recent months, with critics saying the tech giant wields too much power in the industry. U.S. Senators have griped about the “gatekeeper control” that Apple and Google have with their mobile operating systems, forcing the companies to testify before Congress. And South Korea is poised to become the first country to impose curbs on the companies’ app marketplaces.\nApple’s App Store practices have come under increasing scrutiny in recent months, with critics saying the tech giant wields too much power in the industry. U.S. Senators have griped about the “gatekeeper control” that Apple and Google have with their mobile operating systems and have hauled the companies into congressional hearings. And South Korea is poised to become the first country to impose curbs on the companies’ app marketplaces.\nWith Thursday’s agreement, Apple said it would retain recent changes to the App Store search engine for the next three years. “At the request of developers, Apple has agreed that its Search results will continue to be based on objective characteristics like downloads, star ratings, text relevance and user behavior signals,” Apple said.\nThe Cupertino, California-based company is also expanding the number of price points developers can offer from fewer than 100 to more than 500, and it will publish an annual App Store transparency report.\nThat report “will share meaningful statistics about the app review process, including the number of apps rejected for different reasons, the number of customer and developer accounts deactivated, objective data regarding search queries and results, and the number of apps removed from the App Store,” according to Apple. And the company plans to detail more information about its app review process on its website.","news_type":1},"isVote":1,"tweetType":1,"viewCount":138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819389156,"gmtCreate":1630034048775,"gmtModify":1676530206423,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"So?&nbsp;","listText":"So?&nbsp;","text":"So?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819389156","repostId":"1177482103","repostType":4,"repost":{"id":"1177482103","pubTimestamp":1630032656,"share":"https://www.laohu8.com/m/news/1177482103?lang=&edition=full","pubTime":"2021-08-27 10:50","market":"us","language":"en","title":"Snowflake: Why Jim Cramer Thinks Every Fortune 500 Company Will Be a Customer","url":"https://stock-news.laohu8.com/highlight/detail?id=1177482103","media":"Thestreet","summary":"Cloud software company Snowflake (SNOW) reported a second-quarter loss of 64 cents a share onrevenue","content":"<p>Cloud software company Snowflake&nbsp;(<b>SNOW</b>)&nbsp;reported a second-quarter loss of 64 cents a share onrevenue of $272.2 million, up 104% from a year earlier.</p>\n<p>Snowflake CEO Frank Slootman told Jim Cramer on \"Mad Money\" that Snowflake doesn't create demand for its products, it enables it. A lot more is possible with Snowflake when technology no longer holds companies back, Slootman said.</p>\n<p>Cramer told Action Alerts PLUS senior analyst Jeff Marks that Snowflake's 'pay as you go' use model will make it so every customer in the Fortune 500 is a customer.</p>\n<p>\"[Snowflake] is the way of the future, right now,\" Cramer said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Snowflake: Why Jim Cramer Thinks Every Fortune 500 Company Will Be a Customer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSnowflake: Why Jim Cramer Thinks Every Fortune 500 Company Will Be a Customer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/jim-cramer/jim-cramer-snowflake-customers-every-fortune-500-company><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cloud software company Snowflake (SNOW) reported a second-quarter loss of 64 cents a share onrevenue of $272.2 million, up 104% from a year earlier.\nSnowflake CEO Frank Slootman told Jim Cramer on \"...</p>\n\n<a href=\"https://www.thestreet.com/jim-cramer/jim-cramer-snowflake-customers-every-fortune-500-company\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNOW":"Snowflake"},"source_url":"https://www.thestreet.com/jim-cramer/jim-cramer-snowflake-customers-every-fortune-500-company","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177482103","content_text":"Cloud software company Snowflake (SNOW) reported a second-quarter loss of 64 cents a share onrevenue of $272.2 million, up 104% from a year earlier.\nSnowflake CEO Frank Slootman told Jim Cramer on \"Mad Money\" that Snowflake doesn't create demand for its products, it enables it. A lot more is possible with Snowflake when technology no longer holds companies back, Slootman said.\nCramer told Action Alerts PLUS senior analyst Jeff Marks that Snowflake's 'pay as you go' use model will make it so every customer in the Fortune 500 is a customer.\n\"[Snowflake] is the way of the future, right now,\" Cramer said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":51,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837263946,"gmtCreate":1629894255885,"gmtModify":1676530164351,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Going places","listText":"Going places","text":"Going places","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/837263946","repostId":"1191562313","repostType":4,"isVote":1,"tweetType":1,"viewCount":47,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834337045,"gmtCreate":1629771259487,"gmtModify":1676530125919,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Hit 2000!!!!","listText":"Hit 2000!!!!","text":"Hit 2000!!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834337045","repostId":"2161084667","repostType":4,"repost":{"id":"2161084667","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1629768307,"share":"https://www.laohu8.com/m/news/2161084667?lang=&edition=full","pubTime":"2021-08-24 09:25","market":"fut","language":"en","title":"Gold hovers above $1,800 as early taper expectations cool","url":"https://stock-news.laohu8.com/highlight/detail?id=2161084667","media":"Reuters","summary":"Aug 24 (Reuters) - Gold prices fell slightly on Tuesday, although they hovered above the key psychol","content":"<p>Aug 24 (Reuters) - Gold prices fell slightly on Tuesday, although they hovered above the key psychological level of $1,800 on expectations that the U.S. Federal Reserve might delay cutting back its stimulus amid rising cases of the Delta coronavirus variant.</p>\n<p>FUNDAMENTALS</p>\n<p>* Spot gold&nbsp;eased 0.2% to $1,801.78 per ounce by 0100 GMT, having jumped about 1.4% in the previous session.</p>\n<p>* U.S. gold futures&nbsp;were little changed at $1,804.90.</p>\n<p>* The dollar index&nbsp;clawed higher after falling about 0.6% on Monday.</p>\n<p>* Data from IHS <a href=\"https://laohu8.com/S/MRKT\">Markit</a> showed U.S. business activity growth slowed for a third straight month in August as capacity constraints, supply shortages and the rapidly spreading Delta variant weakened the momentum of the rebound from last year's pandemic-induced recession.</p>\n<p>* Investors are now focused on Fed Chair Jerome Powell's speech at the annual Jackson Hole, Wyoming, symposium awaiting guidance on the U.S. central bank's taper plans.</p>\n<p>* Britain's post-lockdown economic rebound slowed sharply in August as companies struggled with unprecedented shortages of staff and materials, though strong inflation pressures cooled a bit, a survey showed on Monday.</p>\n<p>* SPDR Gold Trust, the world's largest gold-backed exchange-traded fund, said its holdings fell 0.5% to 1,006.66 tonnes on Monday from 1,011.61 tonnes on Friday.</p>\n<p>* Silver&nbsp;fell 0.5% to $23.54 per ounce, while platinum edged 0.3% higher to $1,015.92.</p>\n<p>* Palladium&nbsp;was steady at $2,401.13, having risen 5.5% in the previous session.</p>\n<p>DATA/EVENTS <a href=\"https://laohu8.com/S/GMT\">$(GMT)$</a> 0600 Germany GDP Detailed QQ SA Q2 0600 Germany GDP Detailed YY NSA Q2 1400 US New Home Sales-Units July</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gold hovers above $1,800 as early taper expectations cool</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGold hovers above $1,800 as early taper expectations cool\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-24 09:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 24 (Reuters) - Gold prices fell slightly on Tuesday, although they hovered above the key psychological level of $1,800 on expectations that the U.S. Federal Reserve might delay cutting back its stimulus amid rising cases of the Delta coronavirus variant.</p>\n<p>FUNDAMENTALS</p>\n<p>* Spot gold&nbsp;eased 0.2% to $1,801.78 per ounce by 0100 GMT, having jumped about 1.4% in the previous session.</p>\n<p>* U.S. gold futures&nbsp;were little changed at $1,804.90.</p>\n<p>* The dollar index&nbsp;clawed higher after falling about 0.6% on Monday.</p>\n<p>* Data from IHS <a href=\"https://laohu8.com/S/MRKT\">Markit</a> showed U.S. business activity growth slowed for a third straight month in August as capacity constraints, supply shortages and the rapidly spreading Delta variant weakened the momentum of the rebound from last year's pandemic-induced recession.</p>\n<p>* Investors are now focused on Fed Chair Jerome Powell's speech at the annual Jackson Hole, Wyoming, symposium awaiting guidance on the U.S. central bank's taper plans.</p>\n<p>* Britain's post-lockdown economic rebound slowed sharply in August as companies struggled with unprecedented shortages of staff and materials, though strong inflation pressures cooled a bit, a survey showed on Monday.</p>\n<p>* SPDR Gold Trust, the world's largest gold-backed exchange-traded fund, said its holdings fell 0.5% to 1,006.66 tonnes on Monday from 1,011.61 tonnes on Friday.</p>\n<p>* Silver&nbsp;fell 0.5% to $23.54 per ounce, while platinum edged 0.3% higher to $1,015.92.</p>\n<p>* Palladium&nbsp;was steady at $2,401.13, having risen 5.5% in the previous session.</p>\n<p>DATA/EVENTS <a href=\"https://laohu8.com/S/GMT\">$(GMT)$</a> 0600 Germany GDP Detailed QQ SA Q2 0600 Germany GDP Detailed YY NSA Q2 1400 US New Home Sales-Units July</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"159934":"黄金ETF","518880":"黄金ETF","NUGT":"二倍做多黄金矿业指数ETF-Direxion","GLD":"SPDR黄金ETF","DUST":"二倍做空黄金矿业指数ETF-Direxion","GDX":"黄金矿业ETF-VanEck","IAU":"黄金信托ETF(iShares)"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161084667","content_text":"Aug 24 (Reuters) - Gold prices fell slightly on Tuesday, although they hovered above the key psychological level of $1,800 on expectations that the U.S. Federal Reserve might delay cutting back its stimulus amid rising cases of the Delta coronavirus variant.\nFUNDAMENTALS\n* Spot gold eased 0.2% to $1,801.78 per ounce by 0100 GMT, having jumped about 1.4% in the previous session.\n* U.S. gold futures were little changed at $1,804.90.\n* The dollar index clawed higher after falling about 0.6% on Monday.\n* Data from IHS Markit showed U.S. business activity growth slowed for a third straight month in August as capacity constraints, supply shortages and the rapidly spreading Delta variant weakened the momentum of the rebound from last year's pandemic-induced recession.\n* Investors are now focused on Fed Chair Jerome Powell's speech at the annual Jackson Hole, Wyoming, symposium awaiting guidance on the U.S. central bank's taper plans.\n* Britain's post-lockdown economic rebound slowed sharply in August as companies struggled with unprecedented shortages of staff and materials, though strong inflation pressures cooled a bit, a survey showed on Monday.\n* SPDR Gold Trust, the world's largest gold-backed exchange-traded fund, said its holdings fell 0.5% to 1,006.66 tonnes on Monday from 1,011.61 tonnes on Friday.\n* Silver fell 0.5% to $23.54 per ounce, while platinum edged 0.3% higher to $1,015.92.\n* Palladium was steady at $2,401.13, having risen 5.5% in the previous session.\nDATA/EVENTS $(GMT)$ 0600 Germany GDP Detailed QQ SA Q2 0600 Germany GDP Detailed YY NSA Q2 1400 US New Home Sales-Units July","news_type":1},"isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832641671,"gmtCreate":1629627683993,"gmtModify":1676530082155,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Noooooo","listText":"Noooooo","text":"Noooooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/832641671","repostId":"2161743804","repostType":4,"isVote":1,"tweetType":1,"viewCount":115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836347567,"gmtCreate":1629460292359,"gmtModify":1676530047947,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Buy?&nbsp;","listText":"Buy?&nbsp;","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836347567","repostId":"1126467168","repostType":4,"repost":{"id":"1126467168","pubTimestamp":1629457958,"share":"https://www.laohu8.com/m/news/1126467168?lang=&edition=full","pubTime":"2021-08-20 19:12","market":"us","language":"en","title":"Spotify announces $1B share repurchase program","url":"https://stock-news.laohu8.com/highlight/detail?id=1126467168","media":"seekingalpha","summary":"The board of directors of Spotify Technology(NYSE:SPOT)hasauthorizedto repurchase 10M company’s ordi","content":"<p>The board of directors of Spotify Technology(NYSE:SPOT)hasauthorizedto repurchase 10M company’s ordinary shares, up to the amountof $1B, representing 2.5% of the market-cap of $39.31B.</p>\n<p>Buyback will begin in 3Q21 and will expire on April 21, 2026.</p>\n<p>“This announcement demonstrates our confidence in Spotify’s business and the growth opportunities we see over the long term,” said Paul Vogel, Chief Financial Officer at Spotify. “We believe this is an attractive use of capital, and based on the strength of our balance sheet, we continue to see ample opportunity to invest and grow our business.”</p>\n<p>Shares up&nbsp;1.13%&nbsp;premarket.</p>\n<p><img src=\"https://static.tigerbbs.com/72c9b33d569de9076441f28367f46cab\" tg-width=\"912\" tg-height=\"388\" referrerpolicy=\"no-referrer\"></p>\n<p>A quick look at company's current ownership status, ~58.5% of shares outstanding are owned by institutions and 13.25% by Public and Other:</p>\n<p><img src=\"https://static.tigerbbs.com/1c9748658811600fb599664a784273c3\" tg-width=\"676\" tg-height=\"174\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spotify announces $1B share repurchase program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpotify announces $1B share repurchase program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 19:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3732598-spotify-announces-1b-share-repurchase-program><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The board of directors of Spotify Technology(NYSE:SPOT)hasauthorizedto repurchase 10M company’s ordinary shares, up to the amountof $1B, representing 2.5% of the market-cap of $39.31B.\nBuyback will ...</p>\n\n<a href=\"https://seekingalpha.com/news/3732598-spotify-announces-1b-share-repurchase-program\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPOT":"Spotify Technology S.A."},"source_url":"https://seekingalpha.com/news/3732598-spotify-announces-1b-share-repurchase-program","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1126467168","content_text":"The board of directors of Spotify Technology(NYSE:SPOT)hasauthorizedto repurchase 10M company’s ordinary shares, up to the amountof $1B, representing 2.5% of the market-cap of $39.31B.\nBuyback will begin in 3Q21 and will expire on April 21, 2026.\n“This announcement demonstrates our confidence in Spotify’s business and the growth opportunities we see over the long term,” said Paul Vogel, Chief Financial Officer at Spotify. “We believe this is an attractive use of capital, and based on the strength of our balance sheet, we continue to see ample opportunity to invest and grow our business.”\nShares up 1.13% premarket.\n\nA quick look at company's current ownership status, ~58.5% of shares outstanding are owned by institutions and 13.25% by Public and Other:","news_type":1},"isVote":1,"tweetType":1,"viewCount":64,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831522442,"gmtCreate":1629336361486,"gmtModify":1676530006189,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Wats new","listText":"Wats new","text":"Wats new","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/831522442","repostId":"1173912409","repostType":4,"repost":{"id":"1173912409","pubTimestamp":1629328047,"share":"https://www.laohu8.com/m/news/1173912409?lang=&edition=full","pubTime":"2021-08-19 07:07","market":"us","language":"en","title":"Stocks End the Day in an Ugly Way After Fed Minutes Show Taper Talk Is Serious","url":"https://stock-news.laohu8.com/highlight/detail?id=1173912409","media":"Barrons","summary":"Stocks sold off Wednesday after the release of the minutes of the Federal Reserve’s July meeting.\nTh","content":"<p>Stocks sold off Wednesday after the release of the minutes of the Federal Reserve’s July meeting.</p>\n<p>The&nbsp;Dow Jones Industrial Average&nbsp;dropped 383 points, or 1.1%, while the S&amp;P 500&nbsp;fell 1.1%. The Nasdaq Composite&nbsp;declined 0.9%. All three finished near their lows of the day.</p>\n<p>Fed governors have been dropping hints in recent weeks that the beginning of the end of the central bank’s bond buying was nearing, and the minutes confirmed that&nbsp;taperingis at hand. “Most participants noted that …it could be appropriate to start reducing the pace of asset purchases this year,” the minutes read.</p>\n<p>The assessment comes as&nbsp;the economy has recovered quickly, and reflects that the Fed is now focused on when—and how quickly—to remove support from the economy.</p>\n<p>The selloff was broad. About 83% of S&amp;P 500 stocks fell on the day, according to FactSet. This dynamics often reflects concern about how the market will perform without the Fed there to support it.</p>\n<p>Now, it’s just a question of when tapering will begin. It’ “is going to be September or December,” said Dave Wagner, portfolio manager and analyst at Aptus Capital Advisors. “Everyone is focusing on Jackson Hole in my opinion,” he continued, referring to the conclave of central bankers that occurs later this month in Jackson Hole, Wyo.</p>\n<p>Strangely, the bond market didn’t react all that much, with the 10-year Treasury yield closing at 1.27%, where it hovered for most of the day. The 2-year yield, which often moves higher when market participants see the Fed hiking short-term interest rates sooner, ended at 0.21%, lower than the 0.22% it hit in the morning.</p>\n<p>“I don’t think we’ve learned anything new,” said Tom Graff, head of fixed income at Brown Advisory. Graff added that the consensus for a short-term interest rate hikes in 2022 or 2023 hasn’t changed.</p>\n<p>A weak market, however, couldn’t keep some stocks down. For some, it was about earnings.Lowe’s&nbsp;(ticker: LOW) stock rose 9.6% after&nbsp;reporting a profit&nbsp;of $4.25 a share, beating estimates of $4.01 a share, on sales of $27.6 billion, above expectations for $26.9 billion.TJX&nbsp;(TJX) stock rose 6% after reporting&nbsp;a profit&nbsp;of 64 cents a share, beating estimates of 59 cents a share, on sales of $12.1 billion, above expectations for $11 billion.</p>\n<p>Others were buoyed by analyst upgrades, with ViacomCBS (VIAC) stock rose 3.7% after getting upgraded to Overweight from Equal Weight at Wells Fargo, and BlackBerry (BB) stock gained 4.2% after getting upgraded to Hold from Sell at Canaccord Genuity.</p>\n<p>Tilray&nbsp;(TLRY) stock rose 1.1% after the company bought senior secured convertible notes in marijuana company&nbsp;MedMen Enterprises.&nbsp;The notes would convert into an equity stake if&nbsp;cannabis is legalized in the U.S.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks End the Day in an Ugly Way After Fed Minutes Show Taper Talk Is Serious</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks End the Day in an Ugly Way After Fed Minutes Show Taper Talk Is Serious\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-19 07:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stock-market-today-51629283162?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks sold off Wednesday after the release of the minutes of the Federal Reserve’s July meeting.\nThe Dow Jones Industrial Average dropped 383 points, or 1.1%, while the S&P 500 fell 1.1%. The Nasdaq ...</p>\n\n<a href=\"https://www.barrons.com/articles/stock-market-today-51629283162?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BB":"黑莓",".DJI":"道琼斯","LOW":"劳氏",".IXIC":"NASDAQ Composite","TJX":"The TJX Companies Inc.","TLRY":"Tilray Inc.",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/stock-market-today-51629283162?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173912409","content_text":"Stocks sold off Wednesday after the release of the minutes of the Federal Reserve’s July meeting.\nThe Dow Jones Industrial Average dropped 383 points, or 1.1%, while the S&P 500 fell 1.1%. The Nasdaq Composite declined 0.9%. All three finished near their lows of the day.\nFed governors have been dropping hints in recent weeks that the beginning of the end of the central bank’s bond buying was nearing, and the minutes confirmed that taperingis at hand. “Most participants noted that …it could be appropriate to start reducing the pace of asset purchases this year,” the minutes read.\nThe assessment comes as the economy has recovered quickly, and reflects that the Fed is now focused on when—and how quickly—to remove support from the economy.\nThe selloff was broad. About 83% of S&P 500 stocks fell on the day, according to FactSet. This dynamics often reflects concern about how the market will perform without the Fed there to support it.\nNow, it’s just a question of when tapering will begin. It’ “is going to be September or December,” said Dave Wagner, portfolio manager and analyst at Aptus Capital Advisors. “Everyone is focusing on Jackson Hole in my opinion,” he continued, referring to the conclave of central bankers that occurs later this month in Jackson Hole, Wyo.\nStrangely, the bond market didn’t react all that much, with the 10-year Treasury yield closing at 1.27%, where it hovered for most of the day. The 2-year yield, which often moves higher when market participants see the Fed hiking short-term interest rates sooner, ended at 0.21%, lower than the 0.22% it hit in the morning.\n“I don’t think we’ve learned anything new,” said Tom Graff, head of fixed income at Brown Advisory. Graff added that the consensus for a short-term interest rate hikes in 2022 or 2023 hasn’t changed.\nA weak market, however, couldn’t keep some stocks down. For some, it was about earnings.Lowe’s (ticker: LOW) stock rose 9.6% after reporting a profit of $4.25 a share, beating estimates of $4.01 a share, on sales of $27.6 billion, above expectations for $26.9 billion.TJX (TJX) stock rose 6% after reporting a profit of 64 cents a share, beating estimates of 59 cents a share, on sales of $12.1 billion, above expectations for $11 billion.\nOthers were buoyed by analyst upgrades, with ViacomCBS (VIAC) stock rose 3.7% after getting upgraded to Overweight from Equal Weight at Wells Fargo, and BlackBerry (BB) stock gained 4.2% after getting upgraded to Hold from Sell at Canaccord Genuity.\nTilray (TLRY) stock rose 1.1% after the company bought senior secured convertible notes in marijuana company MedMen Enterprises. The notes would convert into an equity stake if cannabis is legalized in the U.S.","news_type":1},"isVote":1,"tweetType":1,"viewCount":115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839448259,"gmtCreate":1629177076471,"gmtModify":1676529954899,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Buy this dip","listText":"Buy this dip","text":"Buy this dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/839448259","repostId":"1144644937","repostType":4,"isVote":1,"tweetType":1,"viewCount":103,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839441878,"gmtCreate":1629177027794,"gmtModify":1676529954882,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Boom","listText":"Boom","text":"Boom","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/839441878","repostId":"1139131126","repostType":4,"repost":{"id":"1139131126","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1629176889,"share":"https://www.laohu8.com/m/news/1139131126?lang=&edition=full","pubTime":"2021-08-17 13:08","market":"us","language":"en","title":"Six hurt in Tesla crash in British school car park -Telegraph","url":"https://stock-news.laohu8.com/highlight/detail?id=1139131126","media":"Reuters","summary":"Aug 16 (Reuters) - Five children and an adult were taken to hospital with injuries after a Tesla Inc","content":"<p>Aug 16 (Reuters) - Five children and an adult were taken to hospital with injuries after a Tesla Inc(TSLA.O)Model 3 crashed in a school car park in southern England on Monday, the Telegraph newspaper said.</p>\n<p>At least one person was said to have been pinned under the electric car in the car park in Sussex, the reportsaid, adding that the exact number was not clear.</p>\n<p>The National Health Service's South East Coast Ambulance Servicesaidone person was in critical condition and three had potentially serious injuries.</p>\n<p>It was not known if there was a driver behind the wheel at the time of the collision, the Telegraph added.</p>\n<p>Tesla did not immediately respond to a request for comment.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Six hurt in Tesla crash in British school car park -Telegraph</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSix hurt in Tesla crash in British school car park -Telegraph\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-17 13:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 16 (Reuters) - Five children and an adult were taken to hospital with injuries after a Tesla Inc(TSLA.O)Model 3 crashed in a school car park in southern England on Monday, the Telegraph newspaper said.</p>\n<p>At least one person was said to have been pinned under the electric car in the car park in Sussex, the reportsaid, adding that the exact number was not clear.</p>\n<p>The National Health Service's South East Coast Ambulance Servicesaidone person was in critical condition and three had potentially serious injuries.</p>\n<p>It was not known if there was a driver behind the wheel at the time of the collision, the Telegraph added.</p>\n<p>Tesla did not immediately respond to a request for comment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139131126","content_text":"Aug 16 (Reuters) - Five children and an adult were taken to hospital with injuries after a Tesla Inc(TSLA.O)Model 3 crashed in a school car park in southern England on Monday, the Telegraph newspaper said.\nAt least one person was said to have been pinned under the electric car in the car park in Sussex, the reportsaid, adding that the exact number was not clear.\nThe National Health Service's South East Coast Ambulance Servicesaidone person was in critical condition and three had potentially serious injuries.\nIt was not known if there was a driver behind the wheel at the time of the collision, the Telegraph added.\nTesla did not immediately respond to a request for comment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894294828,"gmtCreate":1628827275764,"gmtModify":1676529867620,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Go go go","listText":"Go go go","text":"Go go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894294828","repostId":"1174192462","repostType":4,"repost":{"id":"1174192462","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628824480,"share":"https://www.laohu8.com/m/news/1174192462?lang=&edition=full","pubTime":"2021-08-13 11:14","market":"us","language":"en","title":"Clover Health, Palantir, SoFi, Wish, Disney And More — Stocks Buzzing On WallStreeBets Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1174192462","media":"Benzinga","summary":"Clover Health Corp continued to be the most-discussed stockon Reddit’s r/WallStreetBets forum as of ","content":"<p><b><a href=\"https://laohu8.com/S/CLOV\">Clover Health Corp</a></b>&nbsp;continued to be the most-discussed stockon Reddit’s r/WallStreetBets forum as of Thursday night, while<b>&nbsp;<a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/SOFI\">SoFi Technologies Inc.</a> </b>and&nbsp;<b><a href=\"https://laohu8.com/S/WISH\">ContextLogic Inc.</a> </b>are also seeing high interest.</p>\n<p><b>What Happened</b>: Medicare Advantage provider Clover Health is seeing the highest interest on the forum with 901 mentions, followed by software company Palantir Technologies with 659 mentions, data from Quiver Quantitative showed.</p>\n<p>Online personal finance company SoFi Technologies and e-commerce company ContextLogic are in the third and fourth positions, having attracted 642 and 538 mentions, respectively.</p>\n<p>The other stocks that are trending on the forum include exchange-traded fund&nbsp;<b><a href=\"https://laohu8.com/S/SPY\">S&amp;P500 ETF</a></b>, lithium-ion battery maker&nbsp;<b><a href=\"https://laohu8.com/S/MVST\">Microvast Holdings, Inc.</a></b>, media and entertainment giant<b>&nbsp;<a href=\"https://laohu8.com/S/DIS\">Walt Disney</a></b>, biotechnology company&nbsp;<b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b>, chipmaker&nbsp;<b><a href=\"https://laohu8.com/S/MU\">Micron Technology</a></b> and mortgage lender&nbsp;<b><a href=\"https://laohu8.com/S/RKT\">Rocket Companies</a></b>.</p>\n<p><b>Why It Matters</b>: Shares of Clover Health rose in Thursday’s regular trading session after the company&nbsp;reported&nbsp;better-than-expected sales results for the second quarter on Wednesday. Clover Health has 22.47% of its total floatheld short.</p>\n<p>Palantir Technologies&nbsp;reported&nbsp;better-than-expected earnings results for the second quarter, while SoFi Technologies’ shares tumbled in extended trading after the company reported a loss for the third quarter.</p>\n<p>ContextLogic’s shares fell in Thursday’s trading session after the company’s loss for the second quarter&nbsp;widened&nbsp;on lower revenues.</p>\n<p>Disney&nbsp;reported&nbsp;better-than-expected results for the third quarter and also said that Disney+ subscribers doubled from the year-ago period to 116 million.</p>\n<p>Rocket Companies&nbsp;reported&nbsp;second-quarter revenue that missed analysts’ estimates.</p>\n<p><b>Price Action</b>: Clover Health shares closed 10.8% higher in Thursday’s regular trading session at $9.01, but declined 2.3% in the after-hours session to $8.80.</p>\n<p>Palantir Technologies shares closed almost 11.4% higher in the regular trading session at $24.89, but declined 1.6% in the after-hours session to $24.50.</p>\n<p>SoFi Technologies shares closed 3.3% higher in the regular trading session at $17.46, but fell almost 11.9% in the after-hours session to $15.39.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Health, Palantir, SoFi, Wish, Disney And More — Stocks Buzzing On WallStreeBets Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Health, Palantir, SoFi, Wish, Disney And More — Stocks Buzzing On WallStreeBets Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-13 11:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b><a href=\"https://laohu8.com/S/CLOV\">Clover Health Corp</a></b>&nbsp;continued to be the most-discussed stockon Reddit’s r/WallStreetBets forum as of Thursday night, while<b>&nbsp;<a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/SOFI\">SoFi Technologies Inc.</a> </b>and&nbsp;<b><a href=\"https://laohu8.com/S/WISH\">ContextLogic Inc.</a> </b>are also seeing high interest.</p>\n<p><b>What Happened</b>: Medicare Advantage provider Clover Health is seeing the highest interest on the forum with 901 mentions, followed by software company Palantir Technologies with 659 mentions, data from Quiver Quantitative showed.</p>\n<p>Online personal finance company SoFi Technologies and e-commerce company ContextLogic are in the third and fourth positions, having attracted 642 and 538 mentions, respectively.</p>\n<p>The other stocks that are trending on the forum include exchange-traded fund&nbsp;<b><a href=\"https://laohu8.com/S/SPY\">S&amp;P500 ETF</a></b>, lithium-ion battery maker&nbsp;<b><a href=\"https://laohu8.com/S/MVST\">Microvast Holdings, Inc.</a></b>, media and entertainment giant<b>&nbsp;<a href=\"https://laohu8.com/S/DIS\">Walt Disney</a></b>, biotechnology company&nbsp;<b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b>, chipmaker&nbsp;<b><a href=\"https://laohu8.com/S/MU\">Micron Technology</a></b> and mortgage lender&nbsp;<b><a href=\"https://laohu8.com/S/RKT\">Rocket Companies</a></b>.</p>\n<p><b>Why It Matters</b>: Shares of Clover Health rose in Thursday’s regular trading session after the company&nbsp;reported&nbsp;better-than-expected sales results for the second quarter on Wednesday. Clover Health has 22.47% of its total floatheld short.</p>\n<p>Palantir Technologies&nbsp;reported&nbsp;better-than-expected earnings results for the second quarter, while SoFi Technologies’ shares tumbled in extended trading after the company reported a loss for the third quarter.</p>\n<p>ContextLogic’s shares fell in Thursday’s trading session after the company’s loss for the second quarter&nbsp;widened&nbsp;on lower revenues.</p>\n<p>Disney&nbsp;reported&nbsp;better-than-expected results for the third quarter and also said that Disney+ subscribers doubled from the year-ago period to 116 million.</p>\n<p>Rocket Companies&nbsp;reported&nbsp;second-quarter revenue that missed analysts’ estimates.</p>\n<p><b>Price Action</b>: Clover Health shares closed 10.8% higher in Thursday’s regular trading session at $9.01, but declined 2.3% in the after-hours session to $8.80.</p>\n<p>Palantir Technologies shares closed almost 11.4% higher in the regular trading session at $24.89, but declined 1.6% in the after-hours session to $24.50.</p>\n<p>SoFi Technologies shares closed 3.3% higher in the regular trading session at $17.46, but fell almost 11.9% in the after-hours session to $15.39.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RKT":"Rocket Companies","MVST":"Microvast Holdings, Inc.","MRNA":"Moderna, Inc.","CLOV":"Clover Health Corp","MU":"美光科技","PLTR":"Palantir Technologies Inc.","DIS":"迪士尼","SPY":"标普500ETF","SOFI":"SoFi Technologies Inc.","WISH":"ContextLogic Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174192462","content_text":"Clover Health Corp continued to be the most-discussed stockon Reddit’s r/WallStreetBets forum as of Thursday night, while Palantir Technologies Inc., SoFi Technologies Inc. and ContextLogic Inc. are also seeing high interest.\nWhat Happened: Medicare Advantage provider Clover Health is seeing the highest interest on the forum with 901 mentions, followed by software company Palantir Technologies with 659 mentions, data from Quiver Quantitative showed.\nOnline personal finance company SoFi Technologies and e-commerce company ContextLogic are in the third and fourth positions, having attracted 642 and 538 mentions, respectively.\nThe other stocks that are trending on the forum include exchange-traded fund S&P500 ETF, lithium-ion battery maker Microvast Holdings, Inc., media and entertainment giant Walt Disney, biotechnology company Moderna, Inc., chipmaker Micron Technology and mortgage lender Rocket Companies.\nWhy It Matters: Shares of Clover Health rose in Thursday’s regular trading session after the company reported better-than-expected sales results for the second quarter on Wednesday. Clover Health has 22.47% of its total floatheld short.\nPalantir Technologies reported better-than-expected earnings results for the second quarter, while SoFi Technologies’ shares tumbled in extended trading after the company reported a loss for the third quarter.\nContextLogic’s shares fell in Thursday’s trading session after the company’s loss for the second quarter widened on lower revenues.\nDisney reported better-than-expected results for the third quarter and also said that Disney+ subscribers doubled from the year-ago period to 116 million.\nRocket Companies reported second-quarter revenue that missed analysts’ estimates.\nPrice Action: Clover Health shares closed 10.8% higher in Thursday’s regular trading session at $9.01, but declined 2.3% in the after-hours session to $8.80.\nPalantir Technologies shares closed almost 11.4% higher in the regular trading session at $24.89, but declined 1.6% in the after-hours session to $24.50.\nSoFi Technologies shares closed 3.3% higher in the regular trading session at $17.46, but fell almost 11.9% in the after-hours session to $15.39.","news_type":1},"isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":176110132,"gmtCreate":1626870757026,"gmtModify":1703479596431,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Release the vax!&nbsp;","listText":"Release the vax!&nbsp;","text":"Release the vax!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/176110132","repostId":"2153374643","repostType":4,"repost":{"id":"2153374643","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1626870530,"share":"https://www.laohu8.com/m/news/2153374643?lang=&edition=full","pubTime":"2021-07-21 20:28","market":"us","language":"en","title":"Johnson & Johnson Q2 Earnings Beat Expectations; Raises FY21 Outlook, Sees $2.5B Sales From COVID Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2153374643","media":"Benzinga","summary":"Johnson &amp; Johnson (NYSE: JNJ) ","content":"<p><b>Johnson &amp; Johnson&nbsp;</b>(NYSE:&nbsp;JNJ)&nbsp;reported Q2 adjusted earnings&nbsp;of $2.48 per share, almost 50% higher than the $1.67 posted a year ago and better than the consensus of $2.27. Net sales increased 27% Y/Y to $23.3 billion, and ahead of the $22.1 billion consensus.</p>\n<ul>\n <li>Pharmaceutical contributed $12.6 billion in sales, +14%, due to Stelara (ustekinumab), Dazalex (daratumumab), Tremfya (guselkumab), Erleada (apalutamide), Imbruvica (ibrutinib), and paliperidone palmitate.</li>\n <li>This growth was partially offset by biosimilar and generic competition, with declines primarily in Remicade (infliximab).</li>\n <li>Medical Devices grew 58.7% to $6.9 billion, primarily driven by the benefit of market recovery from COVID-19 impacts and the associated deferral of medical procedures.</li>\n <li>Consumer health segment sales increased 10% Y/Y to $3.7 billion, primarily driven by skin health/beauty growth.</li>\n <li><b>Outlook:</b>&nbsp;JNJ raised FY21 guidance and now expects overall sales of $92.5 billion - $93.3 billion, including $2.5 billion - $3 billion from COVID-19 Vaccine sales. In April, it guided for sales of $89.3 billion - $90.3 billion.</li>\n <li>It expects adjusted EPS of $9.60 - $9.70, as against the earlier outlook of $9.42 - $9.57, higher than the consensus of $9.52.</li>\n <li><b>Price Action:</b>&nbsp;JNJ shares are up 0.99% at $170.11 during the premarket session on the last check Wednesday.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/ebb5e7610a65dece0a112ead36e1c2a9\" tg-width=\"704\" tg-height=\"486\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson Q2 Earnings Beat Expectations; Raises FY21 Outlook, Sees $2.5B Sales From COVID Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson Q2 Earnings Beat Expectations; Raises FY21 Outlook, Sees $2.5B Sales From COVID Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-07-21 20:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Johnson &amp; Johnson&nbsp;</b>(NYSE:&nbsp;JNJ)&nbsp;reported Q2 adjusted earnings&nbsp;of $2.48 per share, almost 50% higher than the $1.67 posted a year ago and better than the consensus of $2.27. Net sales increased 27% Y/Y to $23.3 billion, and ahead of the $22.1 billion consensus.</p>\n<ul>\n <li>Pharmaceutical contributed $12.6 billion in sales, +14%, due to Stelara (ustekinumab), Dazalex (daratumumab), Tremfya (guselkumab), Erleada (apalutamide), Imbruvica (ibrutinib), and paliperidone palmitate.</li>\n <li>This growth was partially offset by biosimilar and generic competition, with declines primarily in Remicade (infliximab).</li>\n <li>Medical Devices grew 58.7% to $6.9 billion, primarily driven by the benefit of market recovery from COVID-19 impacts and the associated deferral of medical procedures.</li>\n <li>Consumer health segment sales increased 10% Y/Y to $3.7 billion, primarily driven by skin health/beauty growth.</li>\n <li><b>Outlook:</b>&nbsp;JNJ raised FY21 guidance and now expects overall sales of $92.5 billion - $93.3 billion, including $2.5 billion - $3 billion from COVID-19 Vaccine sales. In April, it guided for sales of $89.3 billion - $90.3 billion.</li>\n <li>It expects adjusted EPS of $9.60 - $9.70, as against the earlier outlook of $9.42 - $9.57, higher than the consensus of $9.52.</li>\n <li><b>Price Action:</b>&nbsp;JNJ shares are up 0.99% at $170.11 during the premarket session on the last check Wednesday.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/ebb5e7610a65dece0a112ead36e1c2a9\" tg-width=\"704\" tg-height=\"486\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QTWO":"Q2 Holdings Inc","JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153374643","content_text":"Johnson & Johnson (NYSE: JNJ) reported Q2 adjusted earnings of $2.48 per share, almost 50% higher than the $1.67 posted a year ago and better than the consensus of $2.27. Net sales increased 27% Y/Y to $23.3 billion, and ahead of the $22.1 billion consensus.\n\nPharmaceutical contributed $12.6 billion in sales, +14%, due to Stelara (ustekinumab), Dazalex (daratumumab), Tremfya (guselkumab), Erleada (apalutamide), Imbruvica (ibrutinib), and paliperidone palmitate.\nThis growth was partially offset by biosimilar and generic competition, with declines primarily in Remicade (infliximab).\nMedical Devices grew 58.7% to $6.9 billion, primarily driven by the benefit of market recovery from COVID-19 impacts and the associated deferral of medical procedures.\nConsumer health segment sales increased 10% Y/Y to $3.7 billion, primarily driven by skin health/beauty growth.\nOutlook: JNJ raised FY21 guidance and now expects overall sales of $92.5 billion - $93.3 billion, including $2.5 billion - $3 billion from COVID-19 Vaccine sales. In April, it guided for sales of $89.3 billion - $90.3 billion.\nIt expects adjusted EPS of $9.60 - $9.70, as against the earlier outlook of $9.42 - $9.57, higher than the consensus of $9.52.\nPrice Action: JNJ shares are up 0.99% at $170.11 during the premarket session on the last check Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":817500468,"gmtCreate":1630972845954,"gmtModify":1676530429651,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"House always wins","listText":"House always wins","text":"House always wins","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/817500468","repostId":"1118832287","repostType":4,"isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126048992,"gmtCreate":1624539688016,"gmtModify":1703839744130,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Rocky roads ahead","listText":"Rocky roads ahead","text":"Rocky roads ahead","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/126048992","repostId":"1195543409","repostType":4,"repost":{"id":"1195543409","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624534898,"share":"https://www.laohu8.com/m/news/1195543409?lang=&edition=full","pubTime":"2021-06-24 19:41","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1195543409","media":"Tiger Newspress","summary":"(Update: June 24, 2021 at 08:31 a.m. ET)\n\nU.S. weekly jobless claims total 411,000, vs 380,000 estim","content":"<p><i><b>(Update: June 24, 2021 at 08:31 a.m. ET)</b></i></p>\n<ul>\n <li><b>U.S. weekly jobless claims total 411,000, vs 380,000 estimate.</b></li>\n <li>Futures jump to all time highs ahead of Fed Speaker, Econ Data frenzy.</li>\n <li>Stock volatility hits fresh pandemic low.</li>\n <li>Eli Lilly stock jumps, Biogen drops on Alzheimer's treatment approval.</li>\n <li>Biogen shares dropped over 5% in premarket trading.</li>\n <li>Eli Lilly, Accenture, Rite Aid &amp; more made the biggest moves in the premarket.</li>\n</ul>\n<p>(June 24)&nbsp;Initial claims for unemployment insurance remained elevated last week as employers struggled to fill a record amount of job openings.</p>\n<p><b>First-time filings totaled 411,000 for the week ended June 19, a slight decrease from the previous total of 418,000 and worse than the 380,000 Dow Jones estimate, the Labor Department reported Thursday.</b></p>\n<p>Stocks rose with U.S. futures Thursday as traders weighed the outlook for recovery and policy support ahead of a slew of economic reports. The pound fell.</p>\n<p>U.S. contracts signaled the S&amp;P 500 Index may regain some momentum after a lull. Eli Lilly &amp; Co. jumped in premarket trading after speeding up its plan to file an application for its Alzheimer’s disease therapy and Accenture Plc rose after boosting its earnings forecast.</p>\n<p>At 7:43 a.m. ET, Dow E-minis were&nbsp;up 172 points, or 0.51%, S&amp;P 500 E-minis rose 19.75 points, or 0.47% and Nasdaq 100 E-minis gained 80 points, or 0.56%.</p>\n<p><img src=\"https://static.tigerbbs.com/dcde37a73640c10a91d2cf227c7b0422\" tg-width=\"1242\" tg-height=\"524\" referrerpolicy=\"no-referrer\"></p>\n<p>Big banks Wells Fargo, Bank of America, Morgan Stanley, Goldman Sachs and JPMorgan Chase &amp; Co added between 0.5% and 1.0%<b>ahead of the Fed's latest stress test results to be revealed at 430pm ET today.</b>Tesla rose 2.7% after Elon Musk said he would list SpaceX’s space internet venture, Starlink, when its cash flow is reasonably predictable, adding that Tesla shareholders could get preference in investing. First Solar climbed as the U.S. was said to be on the verge of barring some solar products made in China’s Xinjiang region. Mega-cap tech names Alphabet, Nvidia, Microsoft, Netflix and Facebook also gained between 0.4% and 0.6%, setting the Nasdaq for a record open. MGM Resorts International rose 2.7% after Deutsche Bank upgraded the casino operator’s stock to “buy” from “hold”.</p>\n<p>Here are some of the biggest U.S. movers today:</p>\n<ul>\n <li>Retail trader favorites gain in premarket trading with Clover Health (CLOV) rising 5.5% and Sundial (SNDL) gaining 6%.</li>\n <li>Daqo New Energy (DQ) drops 6.8% and JinkoSolar (JKS) slides 1.5% with the U.S. poised to block some solar products made in China’s Xinjiang region.</li>\n <li>Information technology services provider DHI Group (DHX) surges 18% after the company’s board authorized a stock buyback program of up to $12 million.</li>\n <li>India Globalization Capital (IGC) rallies 35% after announcing it completed the final cohort of its Phase 1 clinical trial on its tetrahydrocannabinol drug, intended to alleviate Alzheimer’s disease symptoms.</li>\n</ul>\n<p>So far this week, the value index, which includes economy-linked energy, financial and industrial stocks, and its tech-heavy growth counterpart are both up almost 1.8% following the Federal Reserve’s hawkish forecast from a week ago.</p>\n<p>On Wednesday, Dallas Fed President Robert Kaplan said the economy will likely meet the Fed’s threshold for tapering asset purchases sooner than people think, while his Atlanta peer Raphael Bostic said the central bank could decide to slow such purchases in the next few months. Despite the ongoing hawkish commentary, markets pushed higher realizing that the Fed can never again let stocks drop or else the entire ponzi scheme risks collapsing.</p>\n<p>Indeed, stock buyers have shaken off the hawkish turn by the Federal Reserve and are now viewing it as a way to bring inflation under control, according to Sebastien Galy, a Luxembourg-based strategist at Nordea Investment Funds.</p>\n<p><b>\"The interesting development over the past few days suggests that the markets are in a temporary stasis buying on dips as the fear of missing out prevails,\"</b>said Sebastien Galy, senior macro strategist at Nordea Asset Management. “<b>This is evident in the rotation into growth stocks which makes little sense in a time of likely rising interest rates as they are quite leveraged, though not all</b>.\" Still, Galy concluded that&nbsp; “we expect equity markets to continue to rebound in the coming weeks.\"</p>\n<p><b>Stocks making the biggest moves in the premarket: Eli Lilly, Accenture, Rite Aid &amp; more:</b></p>\n<p><b>1)&nbsp;Eli Lilly(LLY) </b>– The drugmaker's shares surged 8.7% in the premarket after Lilly's Alzheimer's treatment received \"breakthrough therapy\" designation from the Food and Drug Administration. The designation means the treatment may show substantial improvement over existing therapies and qualifying it for expedited development and approval.</p>\n<p><b>2)&nbsp;Accenture(ACN) </b>– The consulting firm beat estimates by 17 cents a share, with quarterly profit of $2.40 per share. Revenue topped Street forecasts as well. Accenture saw increasing demand for digital transformation services, with more companies moving to adapt to a hybrid work model. Accenture also raised its full-year forecast, and its stock jumped 4.3% in premarket trading.</p>\n<p><b>3)&nbsp;Rite Aid(RAD)</b> – The drugstore chain reported quarterly earnings of 38 cents per share, 16 cents a share above estimates. Revenue came in slightly short of Wall Street forecasts, however, and its shares fell 6% in the premarket.</p>\n<p><b>4)&nbsp;Darden Restaurants(DRI)</b> – The parent of Olive Garden and other restaurant chainsearned $2.03 per sharefor its latest quarter, compared to a $1.79 a share consensus estimate. Darden's same-restaurant sales surge 90.4% compared to the mid-pandemic year-ago quarter.</p>\n<p><b>5)&nbsp;KB Home(KBH)</b> – KB Home reported quarterly earnings of $1.50 per share, 18 cents a share above estimates. The home builder’s revenue missed Wall Street forecasts, however, despite a selling price increase of 13% and a 145% surge in new orders. KB Home shares lost 4% premarket action.</p>\n<p><b>6)&nbsp;Visa(V)</b> – Visa struck a deal to buy European banking platform Tinkfor about $2.2 billion. The move to acquire the financial data sharing company comes after Visa terminated its planned $5.3 billion acquisition of Plaid following a government lawsuit.</p>\n<p><b>7)&nbsp;Comcast(CMCSA)</b> – The parent of NBCUniversal and CNBC is mulling various ways to dominate video streaming, according to The Wall Street Journal. The paper said CEO Brian Roberts is mulling ideas like a tie-up withViacomCBS(VIAC) or an acquisition ofRoku(ROKU). Comcast told CNBC the story is “pure speculation.” The stock added 1.6% in the premarket.</p>\n<p><b>8)&nbsp;Beyond Meat(BYND)</b> – Some Dunkin’ locations have dropped Beyond Meat’s “Beyond Sausage” breakfast sausage, according to a J.P. Morgan analyst, and a Goldman analyst said a wrap featuring the sausage is likely to suffer the same fate. Dunkin’ told CNBC it continues to have a strong relationship with Beyond Meat and continues to explore new plant-based menu items. Beyond Meat fell 1.3% in the premarket.</p>\n<p><b>9)&nbsp;Steelcase(SCS) </b>– Steelcase surged 5.2% in premarket trading after it reported a smaller-than-expected loss for its latest quarter. The office furniture maker’s revenue also beat Wall Street estimates. The company said revenue will improve on a sequential basis as more workers return to their offices.</p>\n<p><b>10)&nbsp;MGM Resorts(MGM)</b> – MGM Resorts was upgraded to “buy” from “hold” at Deutsche Bank, which said the hotel and casino operator is likely to exceed its targets for profit margin improvement. MGM shares rose 2.3% in premarket trading.</p>\n<p><b>11)&nbsp;Dollar Tree(DLTR) </b>– Dollar Tree was downgraded to “neutral” from “overweight” at Piper Sandler. The firm said the discount retailer will be impacted by rising freight and wage costs that it won’t be able to pass through to customers. The stock fell 1.3% in the premarket.</p>\n<p><b>US Event Calendar</b></p>\n<ul>\n <li>8:30am: May Durable Goods Orders, est. 2.8%, prior -1.3%; Less Transportation, est. 0.7%, prior 1.0%</li>\n <li>8:30am: 1Q GDP Annualized QoQ, est. 6.4%, prior 6.4%</li>\n <li>8:30am: June Initial Jobless Claims, est. 380,000, prior 412,000; Continuing Claims, est. 3.46m, prior 3.52m</li>\n <li>8:30am: May Advance Goods Trade Balance, est. -$87.5b, prior -$85.2b, revised -$85.7b</li>\n <li>8:30am: May Retail Inventories MoM, est. -0.5%, prior -1.6%, revised -1.8%; Wholesale Inventories MoM, est. 0.8%, prior 0.8%</li>\n <li>11am: June Kansas City Fed Manf. Activity, est. 24, prior 26</li>\n <li>430pm: Federal Reserve releases latest stress test results with all big six banks expected to pass&nbsp; paving the way for increased dividends and share buybacks.</li>\n</ul>\n<p><b>Central Bank Speakers</b></p>\n<ul>\n <li>9am: Fed’s Barkin Speaks During Virtual Event</li>\n <li>9:30am: Fed’s Bostic and Harker Speak on Monetary Policy Panel</li>\n <li>11am: Fed’s Williams Takes Part in Moderated Discussion</li>\n <li>1pm: Fed’s Kaplan Discusses Economy</li>\n <li>1pm: Fed’s Bullard Discusses Outlook for Economy and Monetary...</li>\n <li>4pm: Fed’s Barkin Speaks During Virtual Event</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-24 19:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><i><b>(Update: June 24, 2021 at 08:31 a.m. ET)</b></i></p>\n<ul>\n <li><b>U.S. weekly jobless claims total 411,000, vs 380,000 estimate.</b></li>\n <li>Futures jump to all time highs ahead of Fed Speaker, Econ Data frenzy.</li>\n <li>Stock volatility hits fresh pandemic low.</li>\n <li>Eli Lilly stock jumps, Biogen drops on Alzheimer's treatment approval.</li>\n <li>Biogen shares dropped over 5% in premarket trading.</li>\n <li>Eli Lilly, Accenture, Rite Aid &amp; more made the biggest moves in the premarket.</li>\n</ul>\n<p>(June 24)&nbsp;Initial claims for unemployment insurance remained elevated last week as employers struggled to fill a record amount of job openings.</p>\n<p><b>First-time filings totaled 411,000 for the week ended June 19, a slight decrease from the previous total of 418,000 and worse than the 380,000 Dow Jones estimate, the Labor Department reported Thursday.</b></p>\n<p>Stocks rose with U.S. futures Thursday as traders weighed the outlook for recovery and policy support ahead of a slew of economic reports. The pound fell.</p>\n<p>U.S. contracts signaled the S&amp;P 500 Index may regain some momentum after a lull. Eli Lilly &amp; Co. jumped in premarket trading after speeding up its plan to file an application for its Alzheimer’s disease therapy and Accenture Plc rose after boosting its earnings forecast.</p>\n<p>At 7:43 a.m. ET, Dow E-minis were&nbsp;up 172 points, or 0.51%, S&amp;P 500 E-minis rose 19.75 points, or 0.47% and Nasdaq 100 E-minis gained 80 points, or 0.56%.</p>\n<p><img src=\"https://static.tigerbbs.com/dcde37a73640c10a91d2cf227c7b0422\" tg-width=\"1242\" tg-height=\"524\" referrerpolicy=\"no-referrer\"></p>\n<p>Big banks Wells Fargo, Bank of America, Morgan Stanley, Goldman Sachs and JPMorgan Chase &amp; Co added between 0.5% and 1.0%<b>ahead of the Fed's latest stress test results to be revealed at 430pm ET today.</b>Tesla rose 2.7% after Elon Musk said he would list SpaceX’s space internet venture, Starlink, when its cash flow is reasonably predictable, adding that Tesla shareholders could get preference in investing. First Solar climbed as the U.S. was said to be on the verge of barring some solar products made in China’s Xinjiang region. Mega-cap tech names Alphabet, Nvidia, Microsoft, Netflix and Facebook also gained between 0.4% and 0.6%, setting the Nasdaq for a record open. MGM Resorts International rose 2.7% after Deutsche Bank upgraded the casino operator’s stock to “buy” from “hold”.</p>\n<p>Here are some of the biggest U.S. movers today:</p>\n<ul>\n <li>Retail trader favorites gain in premarket trading with Clover Health (CLOV) rising 5.5% and Sundial (SNDL) gaining 6%.</li>\n <li>Daqo New Energy (DQ) drops 6.8% and JinkoSolar (JKS) slides 1.5% with the U.S. poised to block some solar products made in China’s Xinjiang region.</li>\n <li>Information technology services provider DHI Group (DHX) surges 18% after the company’s board authorized a stock buyback program of up to $12 million.</li>\n <li>India Globalization Capital (IGC) rallies 35% after announcing it completed the final cohort of its Phase 1 clinical trial on its tetrahydrocannabinol drug, intended to alleviate Alzheimer’s disease symptoms.</li>\n</ul>\n<p>So far this week, the value index, which includes economy-linked energy, financial and industrial stocks, and its tech-heavy growth counterpart are both up almost 1.8% following the Federal Reserve’s hawkish forecast from a week ago.</p>\n<p>On Wednesday, Dallas Fed President Robert Kaplan said the economy will likely meet the Fed’s threshold for tapering asset purchases sooner than people think, while his Atlanta peer Raphael Bostic said the central bank could decide to slow such purchases in the next few months. Despite the ongoing hawkish commentary, markets pushed higher realizing that the Fed can never again let stocks drop or else the entire ponzi scheme risks collapsing.</p>\n<p>Indeed, stock buyers have shaken off the hawkish turn by the Federal Reserve and are now viewing it as a way to bring inflation under control, according to Sebastien Galy, a Luxembourg-based strategist at Nordea Investment Funds.</p>\n<p><b>\"The interesting development over the past few days suggests that the markets are in a temporary stasis buying on dips as the fear of missing out prevails,\"</b>said Sebastien Galy, senior macro strategist at Nordea Asset Management. “<b>This is evident in the rotation into growth stocks which makes little sense in a time of likely rising interest rates as they are quite leveraged, though not all</b>.\" Still, Galy concluded that&nbsp; “we expect equity markets to continue to rebound in the coming weeks.\"</p>\n<p><b>Stocks making the biggest moves in the premarket: Eli Lilly, Accenture, Rite Aid &amp; more:</b></p>\n<p><b>1)&nbsp;Eli Lilly(LLY) </b>– The drugmaker's shares surged 8.7% in the premarket after Lilly's Alzheimer's treatment received \"breakthrough therapy\" designation from the Food and Drug Administration. The designation means the treatment may show substantial improvement over existing therapies and qualifying it for expedited development and approval.</p>\n<p><b>2)&nbsp;Accenture(ACN) </b>– The consulting firm beat estimates by 17 cents a share, with quarterly profit of $2.40 per share. Revenue topped Street forecasts as well. Accenture saw increasing demand for digital transformation services, with more companies moving to adapt to a hybrid work model. Accenture also raised its full-year forecast, and its stock jumped 4.3% in premarket trading.</p>\n<p><b>3)&nbsp;Rite Aid(RAD)</b> – The drugstore chain reported quarterly earnings of 38 cents per share, 16 cents a share above estimates. Revenue came in slightly short of Wall Street forecasts, however, and its shares fell 6% in the premarket.</p>\n<p><b>4)&nbsp;Darden Restaurants(DRI)</b> – The parent of Olive Garden and other restaurant chainsearned $2.03 per sharefor its latest quarter, compared to a $1.79 a share consensus estimate. Darden's same-restaurant sales surge 90.4% compared to the mid-pandemic year-ago quarter.</p>\n<p><b>5)&nbsp;KB Home(KBH)</b> – KB Home reported quarterly earnings of $1.50 per share, 18 cents a share above estimates. The home builder’s revenue missed Wall Street forecasts, however, despite a selling price increase of 13% and a 145% surge in new orders. KB Home shares lost 4% premarket action.</p>\n<p><b>6)&nbsp;Visa(V)</b> – Visa struck a deal to buy European banking platform Tinkfor about $2.2 billion. The move to acquire the financial data sharing company comes after Visa terminated its planned $5.3 billion acquisition of Plaid following a government lawsuit.</p>\n<p><b>7)&nbsp;Comcast(CMCSA)</b> – The parent of NBCUniversal and CNBC is mulling various ways to dominate video streaming, according to The Wall Street Journal. The paper said CEO Brian Roberts is mulling ideas like a tie-up withViacomCBS(VIAC) or an acquisition ofRoku(ROKU). Comcast told CNBC the story is “pure speculation.” The stock added 1.6% in the premarket.</p>\n<p><b>8)&nbsp;Beyond Meat(BYND)</b> – Some Dunkin’ locations have dropped Beyond Meat’s “Beyond Sausage” breakfast sausage, according to a J.P. Morgan analyst, and a Goldman analyst said a wrap featuring the sausage is likely to suffer the same fate. Dunkin’ told CNBC it continues to have a strong relationship with Beyond Meat and continues to explore new plant-based menu items. Beyond Meat fell 1.3% in the premarket.</p>\n<p><b>9)&nbsp;Steelcase(SCS) </b>– Steelcase surged 5.2% in premarket trading after it reported a smaller-than-expected loss for its latest quarter. The office furniture maker’s revenue also beat Wall Street estimates. The company said revenue will improve on a sequential basis as more workers return to their offices.</p>\n<p><b>10)&nbsp;MGM Resorts(MGM)</b> – MGM Resorts was upgraded to “buy” from “hold” at Deutsche Bank, which said the hotel and casino operator is likely to exceed its targets for profit margin improvement. MGM shares rose 2.3% in premarket trading.</p>\n<p><b>11)&nbsp;Dollar Tree(DLTR) </b>– Dollar Tree was downgraded to “neutral” from “overweight” at Piper Sandler. The firm said the discount retailer will be impacted by rising freight and wage costs that it won’t be able to pass through to customers. The stock fell 1.3% in the premarket.</p>\n<p><b>US Event Calendar</b></p>\n<ul>\n <li>8:30am: May Durable Goods Orders, est. 2.8%, prior -1.3%; Less Transportation, est. 0.7%, prior 1.0%</li>\n <li>8:30am: 1Q GDP Annualized QoQ, est. 6.4%, prior 6.4%</li>\n <li>8:30am: June Initial Jobless Claims, est. 380,000, prior 412,000; Continuing Claims, est. 3.46m, prior 3.52m</li>\n <li>8:30am: May Advance Goods Trade Balance, est. -$87.5b, prior -$85.2b, revised -$85.7b</li>\n <li>8:30am: May Retail Inventories MoM, est. -0.5%, prior -1.6%, revised -1.8%; Wholesale Inventories MoM, est. 0.8%, prior 0.8%</li>\n <li>11am: June Kansas City Fed Manf. Activity, est. 24, prior 26</li>\n <li>430pm: Federal Reserve releases latest stress test results with all big six banks expected to pass&nbsp; paving the way for increased dividends and share buybacks.</li>\n</ul>\n<p><b>Central Bank Speakers</b></p>\n<ul>\n <li>9am: Fed’s Barkin Speaks During Virtual Event</li>\n <li>9:30am: Fed’s Bostic and Harker Speak on Monetary Policy Panel</li>\n <li>11am: Fed’s Williams Takes Part in Moderated Discussion</li>\n <li>1pm: Fed’s Kaplan Discusses Economy</li>\n <li>1pm: Fed’s Bullard Discusses Outlook for Economy and Monetary...</li>\n <li>4pm: Fed’s Barkin Speaks During Virtual Event</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195543409","content_text":"(Update: June 24, 2021 at 08:31 a.m. ET)\n\nU.S. weekly jobless claims total 411,000, vs 380,000 estimate.\nFutures jump to all time highs ahead of Fed Speaker, Econ Data frenzy.\nStock volatility hits fresh pandemic low.\nEli Lilly stock jumps, Biogen drops on Alzheimer's treatment approval.\nBiogen shares dropped over 5% in premarket trading.\nEli Lilly, Accenture, Rite Aid & more made the biggest moves in the premarket.\n\n(June 24) Initial claims for unemployment insurance remained elevated last week as employers struggled to fill a record amount of job openings.\nFirst-time filings totaled 411,000 for the week ended June 19, a slight decrease from the previous total of 418,000 and worse than the 380,000 Dow Jones estimate, the Labor Department reported Thursday.\nStocks rose with U.S. futures Thursday as traders weighed the outlook for recovery and policy support ahead of a slew of economic reports. The pound fell.\nU.S. contracts signaled the S&P 500 Index may regain some momentum after a lull. Eli Lilly & Co. jumped in premarket trading after speeding up its plan to file an application for its Alzheimer’s disease therapy and Accenture Plc rose after boosting its earnings forecast.\nAt 7:43 a.m. ET, Dow E-minis were up 172 points, or 0.51%, S&P 500 E-minis rose 19.75 points, or 0.47% and Nasdaq 100 E-minis gained 80 points, or 0.56%.\n\nBig banks Wells Fargo, Bank of America, Morgan Stanley, Goldman Sachs and JPMorgan Chase & Co added between 0.5% and 1.0%ahead of the Fed's latest stress test results to be revealed at 430pm ET today.Tesla rose 2.7% after Elon Musk said he would list SpaceX’s space internet venture, Starlink, when its cash flow is reasonably predictable, adding that Tesla shareholders could get preference in investing. First Solar climbed as the U.S. was said to be on the verge of barring some solar products made in China’s Xinjiang region. Mega-cap tech names Alphabet, Nvidia, Microsoft, Netflix and Facebook also gained between 0.4% and 0.6%, setting the Nasdaq for a record open. MGM Resorts International rose 2.7% after Deutsche Bank upgraded the casino operator’s stock to “buy” from “hold”.\nHere are some of the biggest U.S. movers today:\n\nRetail trader favorites gain in premarket trading with Clover Health (CLOV) rising 5.5% and Sundial (SNDL) gaining 6%.\nDaqo New Energy (DQ) drops 6.8% and JinkoSolar (JKS) slides 1.5% with the U.S. poised to block some solar products made in China’s Xinjiang region.\nInformation technology services provider DHI Group (DHX) surges 18% after the company’s board authorized a stock buyback program of up to $12 million.\nIndia Globalization Capital (IGC) rallies 35% after announcing it completed the final cohort of its Phase 1 clinical trial on its tetrahydrocannabinol drug, intended to alleviate Alzheimer’s disease symptoms.\n\nSo far this week, the value index, which includes economy-linked energy, financial and industrial stocks, and its tech-heavy growth counterpart are both up almost 1.8% following the Federal Reserve’s hawkish forecast from a week ago.\nOn Wednesday, Dallas Fed President Robert Kaplan said the economy will likely meet the Fed’s threshold for tapering asset purchases sooner than people think, while his Atlanta peer Raphael Bostic said the central bank could decide to slow such purchases in the next few months. Despite the ongoing hawkish commentary, markets pushed higher realizing that the Fed can never again let stocks drop or else the entire ponzi scheme risks collapsing.\nIndeed, stock buyers have shaken off the hawkish turn by the Federal Reserve and are now viewing it as a way to bring inflation under control, according to Sebastien Galy, a Luxembourg-based strategist at Nordea Investment Funds.\n\"The interesting development over the past few days suggests that the markets are in a temporary stasis buying on dips as the fear of missing out prevails,\"said Sebastien Galy, senior macro strategist at Nordea Asset Management. “This is evident in the rotation into growth stocks which makes little sense in a time of likely rising interest rates as they are quite leveraged, though not all.\" Still, Galy concluded that  “we expect equity markets to continue to rebound in the coming weeks.\"\nStocks making the biggest moves in the premarket: Eli Lilly, Accenture, Rite Aid & more:\n1) Eli Lilly(LLY) – The drugmaker's shares surged 8.7% in the premarket after Lilly's Alzheimer's treatment received \"breakthrough therapy\" designation from the Food and Drug Administration. The designation means the treatment may show substantial improvement over existing therapies and qualifying it for expedited development and approval.\n2) Accenture(ACN) – The consulting firm beat estimates by 17 cents a share, with quarterly profit of $2.40 per share. Revenue topped Street forecasts as well. Accenture saw increasing demand for digital transformation services, with more companies moving to adapt to a hybrid work model. Accenture also raised its full-year forecast, and its stock jumped 4.3% in premarket trading.\n3) Rite Aid(RAD) – The drugstore chain reported quarterly earnings of 38 cents per share, 16 cents a share above estimates. Revenue came in slightly short of Wall Street forecasts, however, and its shares fell 6% in the premarket.\n4) Darden Restaurants(DRI) – The parent of Olive Garden and other restaurant chainsearned $2.03 per sharefor its latest quarter, compared to a $1.79 a share consensus estimate. Darden's same-restaurant sales surge 90.4% compared to the mid-pandemic year-ago quarter.\n5) KB Home(KBH) – KB Home reported quarterly earnings of $1.50 per share, 18 cents a share above estimates. The home builder’s revenue missed Wall Street forecasts, however, despite a selling price increase of 13% and a 145% surge in new orders. KB Home shares lost 4% premarket action.\n6) Visa(V) – Visa struck a deal to buy European banking platform Tinkfor about $2.2 billion. The move to acquire the financial data sharing company comes after Visa terminated its planned $5.3 billion acquisition of Plaid following a government lawsuit.\n7) Comcast(CMCSA) – The parent of NBCUniversal and CNBC is mulling various ways to dominate video streaming, according to The Wall Street Journal. The paper said CEO Brian Roberts is mulling ideas like a tie-up withViacomCBS(VIAC) or an acquisition ofRoku(ROKU). Comcast told CNBC the story is “pure speculation.” The stock added 1.6% in the premarket.\n8) Beyond Meat(BYND) – Some Dunkin’ locations have dropped Beyond Meat’s “Beyond Sausage” breakfast sausage, according to a J.P. Morgan analyst, and a Goldman analyst said a wrap featuring the sausage is likely to suffer the same fate. Dunkin’ told CNBC it continues to have a strong relationship with Beyond Meat and continues to explore new plant-based menu items. Beyond Meat fell 1.3% in the premarket.\n9) Steelcase(SCS) – Steelcase surged 5.2% in premarket trading after it reported a smaller-than-expected loss for its latest quarter. The office furniture maker’s revenue also beat Wall Street estimates. The company said revenue will improve on a sequential basis as more workers return to their offices.\n10) MGM Resorts(MGM) – MGM Resorts was upgraded to “buy” from “hold” at Deutsche Bank, which said the hotel and casino operator is likely to exceed its targets for profit margin improvement. MGM shares rose 2.3% in premarket trading.\n11) Dollar Tree(DLTR) – Dollar Tree was downgraded to “neutral” from “overweight” at Piper Sandler. The firm said the discount retailer will be impacted by rising freight and wage costs that it won’t be able to pass through to customers. The stock fell 1.3% in the premarket.\nUS Event Calendar\n\n8:30am: May Durable Goods Orders, est. 2.8%, prior -1.3%; Less Transportation, est. 0.7%, prior 1.0%\n8:30am: 1Q GDP Annualized QoQ, est. 6.4%, prior 6.4%\n8:30am: June Initial Jobless Claims, est. 380,000, prior 412,000; Continuing Claims, est. 3.46m, prior 3.52m\n8:30am: May Advance Goods Trade Balance, est. -$87.5b, prior -$85.2b, revised -$85.7b\n8:30am: May Retail Inventories MoM, est. -0.5%, prior -1.6%, revised -1.8%; Wholesale Inventories MoM, est. 0.8%, prior 0.8%\n11am: June Kansas City Fed Manf. Activity, est. 24, prior 26\n430pm: Federal Reserve releases latest stress test results with all big six banks expected to pass  paving the way for increased dividends and share buybacks.\n\nCentral Bank Speakers\n\n9am: Fed’s Barkin Speaks During Virtual Event\n9:30am: Fed’s Bostic and Harker Speak on Monetary Policy Panel\n11am: Fed’s Williams Takes Part in Moderated Discussion\n1pm: Fed’s Kaplan Discusses Economy\n1pm: Fed’s Bullard Discusses Outlook for Economy and Monetary...\n4pm: Fed’s Barkin Speaks During Virtual Event","news_type":1},"isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832641671,"gmtCreate":1629627683993,"gmtModify":1676530082155,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Noooooo","listText":"Noooooo","text":"Noooooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/832641671","repostId":"2161743804","repostType":4,"isVote":1,"tweetType":1,"viewCount":115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895389464,"gmtCreate":1628724396558,"gmtModify":1676529830132,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Apples are good for you","listText":"Apples are good for you","text":"Apples are good for you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/895389464","repostId":"1143297548","repostType":4,"repost":{"id":"1143297548","pubTimestamp":1628695104,"share":"https://www.laohu8.com/m/news/1143297548?lang=&edition=full","pubTime":"2021-08-11 23:18","market":"us","language":"en","title":"Apple’s Next iPhone Shows How It’s Perfected the Game of Inches","url":"https://stock-news.laohu8.com/highlight/detail?id=1143297548","media":"Bloomberg","summary":"There are three things you can safely predict about each new generation of iPhone: It will have a better camera than its predecessor, a faster processor, and Tim Cook,Apple Inc.’s chief executive officer, will call it the “best iPhone we’ve ever made.”For all the technological wizardry, camera and chip improvements can seem a little uninspiring. The real magic is their effect on Apple’s earnings. Because unlike innovations such as Face ID—the facial recognition system used to unlock iPhones—the ","content":"<p>There are three things you can safely predict about each new generation of iPhone: It will have a better camera than its predecessor, a faster processor, and Tim Cook,Apple Inc.’s chief executive officer, will call it the “best iPhone we’ve ever made.”</p>\n<p>For all the technological wizardry, camera and chip improvements can seem a little uninspiring. The real magic is their effect on Apple’s earnings. Because unlike innovations such as Face ID—the facial recognition system used to unlock iPhones—the chip and camera improvements bring a dual benefit to the Cupertino-based company: Not only do consumers pay a premium for the new features, they also usually end up needing more storage to make the most of those features. And storage, it turns out, is an unbelievable money-printing machine. In fact, it might even be Apple’s secret weapon.</p>\n<p>The next iPhone lineup looks set to turbocharge that approach. Alongside other camera upgrades, the handsets will include a higher-quality video format called ProRes when they’re released in the next few weeks,Bloomberg News reported on Tuesday, as well as more chip updates.</p>\n<p>With every improvement in image quality comes a commensurate increase in storage requirements. The new photo format that Apple added to the iPhone last year, brandedProRaw, is as much as 12 times larger than the standard JPEG. Bigger video files will exacerbate the trend. (That’s especially bad news for those of us whose casual snaps already take up a slightly embarrassing 36 gigabytes.)</p>\n<p>Consumers’ need for more storage is enormously profitable. Where it costs the consumer $100 to add 128 gigabytes of storage, Apple is unlikely to pay more than $20 for the same chip. If you’d prefer to store the data remotely, Apple’s iCloud offering enjoys similar profit margins. Besides, those who have already made the choice to opt for a $1,099 iPhone 12 Pro Max may be less concerned about ponying up more cash for extra capacity.</p>\n<p>Faster download speeds and greater processing power have the same effect. 5G lets you download more data more quickly, but you need the capacity on your device to store it, as do the whiz-bang games enabled by faster chips.</p>\n<p>Apple is reaping the rewards. Its revenue is expected to jump 33%, to an amazing $365 billion, this year, though of course only a slice of that comes from additional memory options. But it shows how canny investment in improving the right technologies can have a multiplicative effect on profit even in the absence of blockbuster new features or flagship products—the average selling price of an iPhone jumped from $748 at the end of 2019 to $938 this March.</p>\n<p>So while we wait for Apple to eventually reveal its Next Big Thing, whether in autonomous cars, smart glasses, or something else entirely, in the meantime the world’s most valuable company is showing just how profitable its game of inches has become.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple’s Next iPhone Shows How It’s Perfected the Game of Inches</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple’s Next iPhone Shows How It’s Perfected the Game of Inches\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-11 23:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-11/new-apple-iphones-show-magic-of-incremental-camera-chip-improvements><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There are three things you can safely predict about each new generation of iPhone: It will have a better camera than its predecessor, a faster processor, and Tim Cook,Apple Inc.’s chief executive ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-11/new-apple-iphones-show-magic-of-incremental-camera-chip-improvements\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-11/new-apple-iphones-show-magic-of-incremental-camera-chip-improvements","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143297548","content_text":"There are three things you can safely predict about each new generation of iPhone: It will have a better camera than its predecessor, a faster processor, and Tim Cook,Apple Inc.’s chief executive officer, will call it the “best iPhone we’ve ever made.”\nFor all the technological wizardry, camera and chip improvements can seem a little uninspiring. The real magic is their effect on Apple’s earnings. Because unlike innovations such as Face ID—the facial recognition system used to unlock iPhones—the chip and camera improvements bring a dual benefit to the Cupertino-based company: Not only do consumers pay a premium for the new features, they also usually end up needing more storage to make the most of those features. And storage, it turns out, is an unbelievable money-printing machine. In fact, it might even be Apple’s secret weapon.\nThe next iPhone lineup looks set to turbocharge that approach. Alongside other camera upgrades, the handsets will include a higher-quality video format called ProRes when they’re released in the next few weeks,Bloomberg News reported on Tuesday, as well as more chip updates.\nWith every improvement in image quality comes a commensurate increase in storage requirements. The new photo format that Apple added to the iPhone last year, brandedProRaw, is as much as 12 times larger than the standard JPEG. Bigger video files will exacerbate the trend. (That’s especially bad news for those of us whose casual snaps already take up a slightly embarrassing 36 gigabytes.)\nConsumers’ need for more storage is enormously profitable. Where it costs the consumer $100 to add 128 gigabytes of storage, Apple is unlikely to pay more than $20 for the same chip. If you’d prefer to store the data remotely, Apple’s iCloud offering enjoys similar profit margins. Besides, those who have already made the choice to opt for a $1,099 iPhone 12 Pro Max may be less concerned about ponying up more cash for extra capacity.\nFaster download speeds and greater processing power have the same effect. 5G lets you download more data more quickly, but you need the capacity on your device to store it, as do the whiz-bang games enabled by faster chips.\nApple is reaping the rewards. Its revenue is expected to jump 33%, to an amazing $365 billion, this year, though of course only a slice of that comes from additional memory options. But it shows how canny investment in improving the right technologies can have a multiplicative effect on profit even in the absence of blockbuster new features or flagship products—the average selling price of an iPhone jumped from $748 at the end of 2019 to $938 this March.\nSo while we wait for Apple to eventually reveal its Next Big Thing, whether in autonomous cars, smart glasses, or something else entirely, in the meantime the world’s most valuable company is showing just how profitable its game of inches has become.","news_type":1},"isVote":1,"tweetType":1,"viewCount":27,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893724719,"gmtCreate":1628302103431,"gmtModify":1703504784480,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Just buy Tesla, NIO and BYD","listText":"Just buy Tesla, NIO and BYD","text":"Just buy Tesla, NIO and BYD","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893724719","repostId":"1143051031","repostType":4,"isVote":1,"tweetType":1,"viewCount":53,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806600632,"gmtCreate":1627652067226,"gmtModify":1703494128781,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Buy in at 150","listText":"Buy in at 150","text":"Buy in at 150","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/806600632","repostId":"1177914270","repostType":4,"repost":{"id":"1177914270","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627650457,"share":"https://www.laohu8.com/m/news/1177914270?lang=&edition=full","pubTime":"2021-07-30 21:07","market":"us","language":"en","title":"Nvidia shares dived 3.2% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1177914270","media":"Tiger Newspress","summary":"Nvidia shares dived 3.2% in premarket trading.China antitrust officials delay review of Nvidia’s $40 Billion Arm Acquisition,according to&nbsp;The Information.","content":"<p>Nvidia shares dived 3.2% in premarket trading.China antitrust officials delay review of Nvidia’s $40 Billion Arm Acquisition,according to&nbsp;The Information.</p>\n<p><img src=\"https://static.tigerbbs.com/bcb434863abbc50b64c8e9d4079a2b06\" tg-width=\"881\" tg-height=\"639\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/395304fa3e2a4eb8436058c29da9628c\" tg-width=\"1222\" tg-height=\"382\" referrerpolicy=\"no-referrer\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nvidia shares dived 3.2% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNvidia shares dived 3.2% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-30 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nvidia shares dived 3.2% in premarket trading.China antitrust officials delay review of Nvidia’s $40 Billion Arm Acquisition,according to&nbsp;The Information.</p>\n<p><img src=\"https://static.tigerbbs.com/bcb434863abbc50b64c8e9d4079a2b06\" tg-width=\"881\" tg-height=\"639\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/395304fa3e2a4eb8436058c29da9628c\" tg-width=\"1222\" tg-height=\"382\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177914270","content_text":"Nvidia shares dived 3.2% in premarket trading.China antitrust officials delay review of Nvidia’s $40 Billion Arm Acquisition,according to The Information.","news_type":1},"isVote":1,"tweetType":1,"viewCount":10,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3585131446723491","authorId":"3585131446723491","name":"Sharon87","avatar":"https://static.tigerbbs.com/85393cfd80f8cbaf580d4968e8a0640a","crmLevel":2,"crmLevelSwitch":0},"content":"Is that possible?","text":"Is that possible?","html":"Is that possible?"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819715090,"gmtCreate":1630107617810,"gmtModify":1676530224710,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Hedging","listText":"Hedging","text":"Hedging","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819715090","repostId":"1199074003","repostType":4,"repost":{"id":"1199074003","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630077382,"share":"https://www.laohu8.com/m/news/1199074003?lang=&edition=full","pubTime":"2021-08-27 23:16","market":"us","language":"en","title":"Crypto stocks surged in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1199074003","media":"Tiger Newspress","summary":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,","content":"<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks surged in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks surged in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-27 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc.","BTCM":"BIT Mining","BTBT":"Bit Digital, Inc.","NCTY":"第九城市","MARA":"Marathon Digital Holdings Inc","CAN":"嘉楠科技","EBON":"亿邦国际","RIOT":"Riot Platforms","SOS":"SOS Limited","SQ":"Block"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199074003","content_text":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase and Paypal climbed between 1% and 13%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806605769,"gmtCreate":1627652303751,"gmtModify":1703494139386,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"$30!!!","listText":"$30!!!","text":"$30!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/806605769","repostId":"1155019271","repostType":4,"repost":{"id":"1155019271","pubTimestamp":1627649979,"share":"https://www.laohu8.com/m/news/1155019271?lang=&edition=full","pubTime":"2021-07-30 20:59","market":"us","language":"en","title":"Palantir Technologies Aspires To Be God Emperor of Data Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=1155019271","media":"InvestorPlace","summary":"Controversy over executives' politics obscures the fact that PLTR stock seems to have cracked the co","content":"<p>Controversy over executives' politics obscures the fact that PLTR stock seems to have cracked the code on high-end data analysis</p>\n<p><b>Palantir Technologies</b>(NYSE:<b><u>PLTR</u></b>) is a belief stock. Since its IPO last September, at $10 a share, the stock has more than doubled investors’ money. PLTR stock looks set to end the month at about $22 a share, it traded as high as $35 in January. Its current market cap is $41.7 billion.</p>\n<p>Believing in Palantir means believing in its data analysis products, called Gotham and Foundry. It also means believing in its controversial CEO,Alex Karp, who took home&nbsp;$1.1 billion&nbsp;in stock options and grants home last year.</p>\n<p>Co-founder Peter Thiel objects to being called“emperor for life,”based on Class F shares giving the co-founders a half-interest in any decision. But you’re buying them, too.</p>\n<p>Palantir had revenue of about $1.1 billion last year. Its March earnings indicate it’s on a path toward&nbsp;$1.6 billion this year.You need belief to pay almost 40 times revenue for anything.</p>\n<p><b>Taking Data Down Market</b></p>\n<p>Palantir started with high-end software for governments and big corporations. Government contracts are still an important metric of its success. The$169 millionfrom civilian and military agencies is important but no more so than for what it says about the software’s acceptance — and penetration — in enterprise markets.</p>\n<p>Foundry for Builders&nbsp;will try to capitalize on this acceptance in smaller, and self-service, markets. The subscription service was enough for our Luke Lango to put out&nbsp;a bullish call&nbsp;on Palantir recently.</p>\n<p>The stock has been&nbsp;buffeted&nbsp;this year by meme investors. Many abandoned it as the pandemic ebbed. But it now has some analysts sending it&nbsp;to the Moon, with an eventual $1 trillion valuation. They see government contracts giving it a moat within that market. They see Palantir’s own&nbsp;investments in SPACs, deploying its cash as a Private Investor in Public Equity (PIPE), as an additional bullish signal for the corporate market.</p>\n<p>Interestingly, of the exchange-traded funds that are holding PLTR stock in their portfolios, among the largest holders are social sentiment-themed funds. The shares are in the top 10 holdings of both&nbsp;<b>VanEck Vectors Social Sentiment ETF</b>(NYSEARCA:<b><u>BUZZ</u></b>),at 2.94% of assets, and&nbsp;<b>SoFi Social 50 ETF</b>(NYSEARCA:<b><u>SFYF</u></b>),at 3.46%.</p>\n<p><b>Have They Cracked the Code?</b></p>\n<p>Many big companies have come-and-gone with big data analysis tools.</p>\n<p><b>Cloudera</b>, which is built on Hadoop, was recently taken privateat $5.3 billionafter flailing in the public market.<b>International Business Machines</b>(NYSE:<b><u>IBM</u></b>) has downsized expectations for Watson, which put a friendly front-end on Hadoop.</p>\n<p>Palantir says Foundry works by&nbsp;integrating&nbsp;back-end data management and front-end analysis. Gotham turns this integration into a&nbsp;virtual operating system, pulling data from multiple sources, integrating them into a single model.</p>\n<p>Palantir next reports results Aug. 10. Analysts are expecting a small profit, 4 cents per share, on revenue of&nbsp;$357 million.&nbsp;That would be only slightly ahead of the March quarter’s $341 million. The expectations for slower growth are bringing out&nbsp;some bears. About&nbsp;13% of the shares&nbsp;were recently being held short.</p>\n<p>To our Alex Sirois, this makes&nbsp;July the perfect time to buy Palantir.If it can show even a small profit the stock could move ahead.</p>\n<p><b>PLTR Stock Valuation Flashes ‘Highly Speculative’</b></p>\n<p>Looking at PLTR stock’s valuation, I see a sign flashing “highly speculative.” It’s trading at&nbsp;34.3 times salesand near 170x forward earnings.</p>\n<p>Yet, what makes it a<i>reasonable</i>speculation is that Palantir is cracking a data analysis code that has frustrated even the Cloud Czars. If Palantir can maintain that expertise, and bring that leadership into the wider enterprise market, this could be a great company.</p>\n<p>Our Chris Markoch says&nbsp;both bulls and bears have it wrong on Palantir, and I agree.</p>\n<p>The politics of Thiel and Karp, and their iron-fisted control of the company, have some investors underestimating the tool. Its positive free cash flow may have some bulls overestimating its value.</p>\n<p>At its current price, however, Palantir is a dirt-cheap speculation. Don’t throw any cash at it that you can’t afford to lose. But if you’ve earned profits elsewhere, and are looking for the next big thing, this may be worth nibbling on.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir Technologies Aspires To Be God Emperor of Data Analysis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir Technologies Aspires To Be God Emperor of Data Analysis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/07/palantir-technologies-aspires-to-be-god-emperor-of-data-analysis/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Controversy over executives' politics obscures the fact that PLTR stock seems to have cracked the code on high-end data analysis\nPalantir Technologies(NYSE:PLTR) is a belief stock. Since its IPO last ...</p>\n\n<a href=\"https://investorplace.com/2021/07/palantir-technologies-aspires-to-be-god-emperor-of-data-analysis/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2021/07/palantir-technologies-aspires-to-be-god-emperor-of-data-analysis/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155019271","content_text":"Controversy over executives' politics obscures the fact that PLTR stock seems to have cracked the code on high-end data analysis\nPalantir Technologies(NYSE:PLTR) is a belief stock. Since its IPO last September, at $10 a share, the stock has more than doubled investors’ money. PLTR stock looks set to end the month at about $22 a share, it traded as high as $35 in January. Its current market cap is $41.7 billion.\nBelieving in Palantir means believing in its data analysis products, called Gotham and Foundry. It also means believing in its controversial CEO,Alex Karp, who took home $1.1 billion in stock options and grants home last year.\nCo-founder Peter Thiel objects to being called“emperor for life,”based on Class F shares giving the co-founders a half-interest in any decision. But you’re buying them, too.\nPalantir had revenue of about $1.1 billion last year. Its March earnings indicate it’s on a path toward $1.6 billion this year.You need belief to pay almost 40 times revenue for anything.\nTaking Data Down Market\nPalantir started with high-end software for governments and big corporations. Government contracts are still an important metric of its success. The$169 millionfrom civilian and military agencies is important but no more so than for what it says about the software’s acceptance — and penetration — in enterprise markets.\nFoundry for Builders will try to capitalize on this acceptance in smaller, and self-service, markets. The subscription service was enough for our Luke Lango to put out a bullish call on Palantir recently.\nThe stock has been buffeted this year by meme investors. Many abandoned it as the pandemic ebbed. But it now has some analysts sending it to the Moon, with an eventual $1 trillion valuation. They see government contracts giving it a moat within that market. They see Palantir’s own investments in SPACs, deploying its cash as a Private Investor in Public Equity (PIPE), as an additional bullish signal for the corporate market.\nInterestingly, of the exchange-traded funds that are holding PLTR stock in their portfolios, among the largest holders are social sentiment-themed funds. The shares are in the top 10 holdings of both VanEck Vectors Social Sentiment ETF(NYSEARCA:BUZZ),at 2.94% of assets, and SoFi Social 50 ETF(NYSEARCA:SFYF),at 3.46%.\nHave They Cracked the Code?\nMany big companies have come-and-gone with big data analysis tools.\nCloudera, which is built on Hadoop, was recently taken privateat $5.3 billionafter flailing in the public market.International Business Machines(NYSE:IBM) has downsized expectations for Watson, which put a friendly front-end on Hadoop.\nPalantir says Foundry works by integrating back-end data management and front-end analysis. Gotham turns this integration into a virtual operating system, pulling data from multiple sources, integrating them into a single model.\nPalantir next reports results Aug. 10. Analysts are expecting a small profit, 4 cents per share, on revenue of $357 million. That would be only slightly ahead of the March quarter’s $341 million. The expectations for slower growth are bringing out some bears. About 13% of the shares were recently being held short.\nTo our Alex Sirois, this makes July the perfect time to buy Palantir.If it can show even a small profit the stock could move ahead.\nPLTR Stock Valuation Flashes ‘Highly Speculative’\nLooking at PLTR stock’s valuation, I see a sign flashing “highly speculative.” It’s trading at 34.3 times salesand near 170x forward earnings.\nYet, what makes it areasonablespeculation is that Palantir is cracking a data analysis code that has frustrated even the Cloud Czars. If Palantir can maintain that expertise, and bring that leadership into the wider enterprise market, this could be a great company.\nOur Chris Markoch says both bulls and bears have it wrong on Palantir, and I agree.\nThe politics of Thiel and Karp, and their iron-fisted control of the company, have some investors underestimating the tool. Its positive free cash flow may have some bulls overestimating its value.\nAt its current price, however, Palantir is a dirt-cheap speculation. Don’t throw any cash at it that you can’t afford to lose. But if you’ve earned profits elsewhere, and are looking for the next big thing, this may be worth nibbling on.","news_type":1},"isVote":1,"tweetType":1,"viewCount":41,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149538103,"gmtCreate":1625734569502,"gmtModify":1703747394314,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Will it be an egg in investors face","listText":"Will it be an egg in investors face","text":"Will it be an egg in investors face","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149538103","repostId":"1149987482","repostType":4,"repost":{"id":"1149987482","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625731317,"share":"https://www.laohu8.com/m/news/1149987482?lang=&edition=full","pubTime":"2021-07-08 16:01","market":"us","language":"en","title":"Newegg shares fell 17% in premarket trading,as rose nearly 150% on Wednesday.","url":"https://stock-news.laohu8.com/highlight/detail?id=1149987482","media":"Tiger Newspress","summary":"Newegg shares fell  17% in premarket trading,as rose nearly 150% on Wednesday.\n\nNewegg is one of the","content":"<p>Newegg&nbsp;shares&nbsp;fell &nbsp;17% in premarket&nbsp;trading,as&nbsp;rose&nbsp;nearly&nbsp;150%&nbsp;on&nbsp;Wednesday.</p>\n<p><img src=\"https://static.tigerbbs.com/b873a3712fb610cafbc3a3696de3f63f\" tg-width=\"1287\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Newegg</b>&nbsp;is one of the largest tech retailers in the country, and now, it’s a retail investor favorite for an upcoming moonshot.</p>\n<p>With the GPU shortage still an issue, Newegg’s recently announced PC parts lottery is a very welcome event. Through the lottery, customers will be able to buy the newest line of GPUs from&nbsp;<b>Nvidia</b>(NASDAQ:<b><u>NVDA</u></b>). The company is also implementing a custom PC building service, allowing the retail giant tocompete with bespoke PC crafterson a commercial level.</p>\n<p>These additions by Newegg are pushing the stock higher. However, there is more driving NEGG stock skyward&nbsp;. It seems social media investors think Newegg could be the next<b>GameStop</b>(NYSE:<b><u>GME</u></b>) or&nbsp;<b>AMC Entertainment</b>(NYSE:<b><u>AMC</u></b>).</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Newegg shares fell 17% in premarket trading,as rose nearly 150% on Wednesday.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNewegg shares fell 17% in premarket trading,as rose nearly 150% on Wednesday.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-08 16:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Newegg&nbsp;shares&nbsp;fell &nbsp;17% in premarket&nbsp;trading,as&nbsp;rose&nbsp;nearly&nbsp;150%&nbsp;on&nbsp;Wednesday.</p>\n<p><img src=\"https://static.tigerbbs.com/b873a3712fb610cafbc3a3696de3f63f\" tg-width=\"1287\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Newegg</b>&nbsp;is one of the largest tech retailers in the country, and now, it’s a retail investor favorite for an upcoming moonshot.</p>\n<p>With the GPU shortage still an issue, Newegg’s recently announced PC parts lottery is a very welcome event. Through the lottery, customers will be able to buy the newest line of GPUs from&nbsp;<b>Nvidia</b>(NASDAQ:<b><u>NVDA</u></b>). The company is also implementing a custom PC building service, allowing the retail giant tocompete with bespoke PC crafterson a commercial level.</p>\n<p>These additions by Newegg are pushing the stock higher. However, there is more driving NEGG stock skyward&nbsp;. It seems social media investors think Newegg could be the next<b>GameStop</b>(NYSE:<b><u>GME</u></b>) or&nbsp;<b>AMC Entertainment</b>(NYSE:<b><u>AMC</u></b>).</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NEGG":"Newegg Comm Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149987482","content_text":"Newegg shares fell  17% in premarket trading,as rose nearly 150% on Wednesday.\n\nNewegg is one of the largest tech retailers in the country, and now, it’s a retail investor favorite for an upcoming moonshot.\nWith the GPU shortage still an issue, Newegg’s recently announced PC parts lottery is a very welcome event. Through the lottery, customers will be able to buy the newest line of GPUs from Nvidia(NASDAQ:NVDA). The company is also implementing a custom PC building service, allowing the retail giant tocompete with bespoke PC crafterson a commercial level.\nThese additions by Newegg are pushing the stock higher. However, there is more driving NEGG stock skyward . It seems social media investors think Newegg could be the nextGameStop(NYSE:GME) or AMC Entertainment(NYSE:AMC).","news_type":1},"isVote":1,"tweetType":1,"viewCount":2,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124418150,"gmtCreate":1624779333270,"gmtModify":1703845061656,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Let's make AMC join the club!&nbsp;","listText":"Let's make AMC join the club!&nbsp;","text":"Let's make AMC join the club!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/124418150","repostId":"1172710941","repostType":4,"isVote":1,"tweetType":1,"viewCount":48,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837263946,"gmtCreate":1629894255885,"gmtModify":1676530164351,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Going places","listText":"Going places","text":"Going places","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/837263946","repostId":"1191562313","repostType":4,"isVote":1,"tweetType":1,"viewCount":47,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893175397,"gmtCreate":1628251429019,"gmtModify":1703503962231,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Crazy price&nbsp;","listText":"Crazy price&nbsp;","text":"Crazy price","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893175397","repostId":"1124982476","repostType":4,"isVote":1,"tweetType":1,"viewCount":2,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899699157,"gmtCreate":1628176399579,"gmtModify":1703502686812,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Buy?&nbsp;","listText":"Buy?&nbsp;","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899699157","repostId":"2157430168","repostType":4,"isVote":1,"tweetType":1,"viewCount":29,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801662408,"gmtCreate":1627515398204,"gmtModify":1703491339092,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"250!","listText":"250!","text":"250!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/801662408","repostId":"1171529765","repostType":4,"repost":{"id":"1171529765","pubTimestamp":1627513623,"share":"https://www.laohu8.com/m/news/1171529765?lang=&edition=full","pubTime":"2021-07-29 07:07","market":"us","language":"en","title":"Facebook's slowdown warning hangs over strong ad sales, while Zuckerberg talks 'metaverse'","url":"https://stock-news.laohu8.com/highlight/detail?id=1171529765","media":"Reuters","summary":"(Reuters) -Facebook Inc said on Wednesday it expects revenue growth to “decelerate significantly,” s","content":"<p>(Reuters) -Facebook Inc said on Wednesday it expects revenue growth to “decelerate significantly,” sending the social media giant’s shares down 3.5% in extended trading even as it reported strong ad sales.</p>\n<p>The warning overshadowed the company’s beat on Wall Street estimates for quarterly revenue, bolstered by increased advertising spending as businesses build their digital presence to cater to consumers spending more time and money online.</p>\n<p>Facebook said it expects Apple’s recent update to its iOS operating system to impact its ability to target ads and therefore ad revenue in the third quarter. The iPhone maker’s privacy changes make it harder for apps to track users and restrict advertisers from accessing valuable data for targeting ads.</p>\n<p>The company also announced on Wednesday that it would require anyone working at its U.S. offices to be vaccinated against COVID-19, joining Alphabet Inc and Netflix.</p>\n<p>Monthly active users came in at 2.90 billion, up 7% from the same period last year but missing analyst expectations of 2.92 billion and marking the slowest growth rate in at least three years, according to IBES data from Refinitiv.</p>\n<p>“The user growth slowdown is notable and highlights the engagement challenges as the world opens up. But importantly, Facebook is the most exposed to Apple’s privacy changes, and it looks like it is starting to have an impact to the outlook beginning in 3Q,” said Ygal Arounian, an analyst at Wedbush Securities.</p>\n<p>Brian Wieser, GroupM’s global president of business intelligence, said all social media companies would see slower growth in the second half of the year and that it would take more concrete warnings about activity in June and July for anyone to anticipate a “meaningful deceleration.”</p>\n<p>Facebook’s total revenue, which primarily consists of ad sales, rose about 56% to $29.08 billion in the second quarter from $18.69 billion a year earlier, beating analysts’ estimates, according to IBES data from Refinitiv.</p>\n<p>Its revenue from advertising rose 56% to $28.58 billion in the second quarter ended June 30, Facebook said. It pointed to a 47% increase in price per ad.</p>\n<p>“In the third and fourth quarters of 2021, we expect year-over-year total revenue growth rates to decelerate significantly on a sequential basis as we lap periods of increasingly strong growth,” Chief Financial Officer Dave Wehner said in the earnings release.</p>\n<p>Net income in the second quarter more than doubled to $10.4 billion, or $3.61 per share. Analysts had expected a profit of $3.03 per share.</p>\n<p>The world’s largest social network has been ramping up its ecommerce efforts, which are expected to bring additional revenue to the company and make its ad inventory more valuable. The push will be key to how Facebook, which hosts more than 1 million online “Shops” on its main app and Instagram, can grow its ad business amid the impact of Apple’s changes.</p>\n<p>It is also on the offensive to attract top social media personalities and their fans, competing with Alphabet’s YouTube and short-video app TikTok, which recently hit 3 billion global downloads. Facebook said this month it would invest more than $1 billion to support content creators through the end of 2022.</p>\n<p>On a conference call with analysts, CEO Mark Zuckerberg also focused on another ambition for the company: the “metaverse.”</p>\n<p>Zuckerberg this week announced that Facebook, which has invested heavily in virtual reality and augmented reality, was setting up a team to work on building a shared digital world, which he is betting will be the successor to the mobile internet. Microsoft also dropped the buzzy Silicon Valley term on its earnings call this week, talking about its own plans for the converging digital and physical worlds.</p>\n<p>“Facebook has its eye on a sci-fi prize,” said Sophie Lund-Yates, equity analyst at Hargreaves Lansdown. “This is little more than an ambition for Facebook at the moment...if the idea comes to fruition, it could be a valuable income source.”</p>\n<p>The company also continues to face pressure from global lawmakers and regulators, including from the U.S. Federal Trade Commission which has until Aug. 19 to refile its antitrust complaint against the company and from a group of states who said on Wednesday they would appeal the judge’s dismissal of their lawsuit. Facebook’s market cap hit $1 trillion for the first time last month when the judge threw out the original complaints.</p>\n<p>The company, which has long been under fire from lawmakers over misinformation and other abuses on its apps, has also come under renewed scrutiny from President Joe Biden’s administration over the handling of false claims about COVID-19. At Facebook’s office in Washington, D.C., on Wednesday, a group of critics set up an installation of body bags to protest the issue.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Facebook's slowdown warning hangs over strong ad sales, while Zuckerberg talks 'metaverse'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFacebook's slowdown warning hangs over strong ad sales, while Zuckerberg talks 'metaverse'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-29 07:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/facebook-results/update-5-facebooks-slowdown-warning-hangs-over-strong-ad-sales-while-zuckerberg-talks-metaverse-idUSL4N2P43YX><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Facebook Inc said on Wednesday it expects revenue growth to “decelerate significantly,” sending the social media giant’s shares down 3.5% in extended trading even as it reported strong ad ...</p>\n\n<a href=\"https://www.reuters.com/article/facebook-results/update-5-facebooks-slowdown-warning-hangs-over-strong-ad-sales-while-zuckerberg-talks-metaverse-idUSL4N2P43YX\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/article/facebook-results/update-5-facebooks-slowdown-warning-hangs-over-strong-ad-sales-while-zuckerberg-talks-metaverse-idUSL4N2P43YX","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171529765","content_text":"(Reuters) -Facebook Inc said on Wednesday it expects revenue growth to “decelerate significantly,” sending the social media giant’s shares down 3.5% in extended trading even as it reported strong ad sales.\nThe warning overshadowed the company’s beat on Wall Street estimates for quarterly revenue, bolstered by increased advertising spending as businesses build their digital presence to cater to consumers spending more time and money online.\nFacebook said it expects Apple’s recent update to its iOS operating system to impact its ability to target ads and therefore ad revenue in the third quarter. The iPhone maker’s privacy changes make it harder for apps to track users and restrict advertisers from accessing valuable data for targeting ads.\nThe company also announced on Wednesday that it would require anyone working at its U.S. offices to be vaccinated against COVID-19, joining Alphabet Inc and Netflix.\nMonthly active users came in at 2.90 billion, up 7% from the same period last year but missing analyst expectations of 2.92 billion and marking the slowest growth rate in at least three years, according to IBES data from Refinitiv.\n“The user growth slowdown is notable and highlights the engagement challenges as the world opens up. But importantly, Facebook is the most exposed to Apple’s privacy changes, and it looks like it is starting to have an impact to the outlook beginning in 3Q,” said Ygal Arounian, an analyst at Wedbush Securities.\nBrian Wieser, GroupM’s global president of business intelligence, said all social media companies would see slower growth in the second half of the year and that it would take more concrete warnings about activity in June and July for anyone to anticipate a “meaningful deceleration.”\nFacebook’s total revenue, which primarily consists of ad sales, rose about 56% to $29.08 billion in the second quarter from $18.69 billion a year earlier, beating analysts’ estimates, according to IBES data from Refinitiv.\nIts revenue from advertising rose 56% to $28.58 billion in the second quarter ended June 30, Facebook said. It pointed to a 47% increase in price per ad.\n“In the third and fourth quarters of 2021, we expect year-over-year total revenue growth rates to decelerate significantly on a sequential basis as we lap periods of increasingly strong growth,” Chief Financial Officer Dave Wehner said in the earnings release.\nNet income in the second quarter more than doubled to $10.4 billion, or $3.61 per share. Analysts had expected a profit of $3.03 per share.\nThe world’s largest social network has been ramping up its ecommerce efforts, which are expected to bring additional revenue to the company and make its ad inventory more valuable. The push will be key to how Facebook, which hosts more than 1 million online “Shops” on its main app and Instagram, can grow its ad business amid the impact of Apple’s changes.\nIt is also on the offensive to attract top social media personalities and their fans, competing with Alphabet’s YouTube and short-video app TikTok, which recently hit 3 billion global downloads. Facebook said this month it would invest more than $1 billion to support content creators through the end of 2022.\nOn a conference call with analysts, CEO Mark Zuckerberg also focused on another ambition for the company: the “metaverse.”\nZuckerberg this week announced that Facebook, which has invested heavily in virtual reality and augmented reality, was setting up a team to work on building a shared digital world, which he is betting will be the successor to the mobile internet. Microsoft also dropped the buzzy Silicon Valley term on its earnings call this week, talking about its own plans for the converging digital and physical worlds.\n“Facebook has its eye on a sci-fi prize,” said Sophie Lund-Yates, equity analyst at Hargreaves Lansdown. “This is little more than an ambition for Facebook at the moment...if the idea comes to fruition, it could be a valuable income source.”\nThe company also continues to face pressure from global lawmakers and regulators, including from the U.S. Federal Trade Commission which has until Aug. 19 to refile its antitrust complaint against the company and from a group of states who said on Wednesday they would appeal the judge’s dismissal of their lawsuit. Facebook’s market cap hit $1 trillion for the first time last month when the judge threw out the original complaints.\nThe company, which has long been under fire from lawmakers over misinformation and other abuses on its apps, has also come under renewed scrutiny from President Joe Biden’s administration over the handling of false claims about COVID-19. At Facebook’s office in Washington, D.C., on Wednesday, a group of critics set up an installation of body bags to protest the issue.","news_type":1},"isVote":1,"tweetType":1,"viewCount":14,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803486613,"gmtCreate":1627457022532,"gmtModify":1703490321070,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Bull long","listText":"Bull long","text":"Bull long","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/803486613","repostId":"1195067283","repostType":4,"repost":{"id":"1195067283","pubTimestamp":1627459353,"share":"https://www.laohu8.com/m/news/1195067283?lang=&edition=full","pubTime":"2021-07-28 16:02","market":"us","language":"en","title":"Apple’s blowout earnings didn’t help its stock, and here’s why","url":"https://stock-news.laohu8.com/highlight/detail?id=1195067283","media":"MarketWatch","summary":"CFO suggests that sales growth will slow overall and in the hot services sector, sending shares lower in after-hours trading despite stunning beat in earnings and iPhone sales. Apple racked up nearly $40 billion in iPhone sales last quarter. BLOOMBERG NEWS. Apple reported its strongest June quarter ever on Tuesday, with a near doubling of its profits and a whopping iPhone beat— iPhone revenue surpassed Wall Street’s expectations by a stunning $5 billion. But the celebration came to a crashing ha","content":"<p>Apple&nbsp;shares&nbsp;fell&nbsp;1.5%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/46b6dcdfd6c3341849a132b84908df8a\" tg-width=\"881\" tg-height=\"638\" referrerpolicy=\"no-referrer\"></p>\n<p>CFO suggests that sales growth will slow overall and in the hot services sector, sending shares lower in after-hours trading despite stunning beat in earnings and iPhone sales</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/df758af59b72a37be435c6d3859ce151\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Apple racked up nearly $40 billion in iPhone sales last quarter. BLOOMBERG NEWS</span></p>\n<p>Apple Inc.’s whopping fiscal third quarter was overshadowed by the company’s forecast for slowing growth Tuesday, putting a damper on its record results and sending shares south.</p>\n<p>Apple&nbsp;reported its strongest June quarter ever on Tuesday, with a near doubling of its profits and a whopping iPhone beat— iPhone revenue surpassed Wall Street’s expectations by a stunning $5 billion. But the celebration came to a crashing halt when Apple Chief Financial Officer Luca Maestri said in a conference call that the company’s revenue growth would slow in the current quarter due to foreign exchange rates, the semiconductor shortage and tougher comparisons with the previous year.</p>\n<p>“We expect very strong double-digit year-over-year revenue growth during the September quarter,” Maestri said, while continuing to avoid exact revenue guidance due to uncertainty related to the COVID-19 pandemic. “We expect revenue growth to be lower than our June quarter year-over-year growth of 36%.”</p>\n<p>Apple’s shares had gained in after-hours trading to that point, but immediately fell back and ultimately ended the extended trading session with a 2% decline.</p>\n<p>Beyond overall revenue, Maestri also warned about one of Apple’s hottest businesses and declined to give any hints about prolonged declines in sales growth.</p>\n<p>“We expect our services growth rate to return to a more typical level,” Maestri said, referring to Apple’s services business, which reached record-high revenue in the quarter by growing 33% to $17.5 billion.</p>\n<p>That growth rate also benefited from a favorable comparison as certain services were significantly impacted by the very beginning of the COVID-19 lockdowns a year ago, he added.</p>\n<p>“We expect significant growth in services, but not to the level that we’ve seen in June,” he said in response to a question about the company’s guidance.</p>\n<p>When asked about the upcoming holiday period, and whether the semiconductor and component shortage would have an impact on what is typically Apple’s biggest quarter, Maestri said he only wanted to talk about one quarter at a time. Some analysts have already been wondering if the second half of this year is going to be as strong as the first half among tech companies, especially the tech giants, and Apple’s June quarter seemed to be reflective of those fears.</p>\n<p>While it seems ridiculous to see shares decline after reporting such a mind-blowing quarter — iPhone total revenue alone was nearly $40 billion and Chief Executive Tim Cook said that 5G penetration is still “very very low, and so we feel really good about the future of the iPhone” — concerns that we are at a peak for tech are valid. And as the delta variant continues to create uncertainty about the path of the COVID-19 pandemic, there is even more uncertainty ahead</p>\n<p>As Cook phrased it Tuesday, “the road to recovery will be a winding one.”</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple’s blowout earnings didn’t help its stock, and here’s why</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple’s blowout earnings didn’t help its stock, and here’s why\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 16:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/apples-blowout-earnings-didnt-help-its-stock-and-heres-why-11627430752?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple shares fell 1.5% in premarket trading.\n\nCFO suggests that sales growth will slow overall and in the hot services sector, sending shares lower in after-hours trading despite stunning beat in ...</p>\n\n<a href=\"https://www.marketwatch.com/story/apples-blowout-earnings-didnt-help-its-stock-and-heres-why-11627430752?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.marketwatch.com/story/apples-blowout-earnings-didnt-help-its-stock-and-heres-why-11627430752?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195067283","content_text":"Apple shares fell 1.5% in premarket trading.\n\nCFO suggests that sales growth will slow overall and in the hot services sector, sending shares lower in after-hours trading despite stunning beat in earnings and iPhone sales\nApple racked up nearly $40 billion in iPhone sales last quarter. BLOOMBERG NEWS\nApple Inc.’s whopping fiscal third quarter was overshadowed by the company’s forecast for slowing growth Tuesday, putting a damper on its record results and sending shares south.\nApple reported its strongest June quarter ever on Tuesday, with a near doubling of its profits and a whopping iPhone beat— iPhone revenue surpassed Wall Street’s expectations by a stunning $5 billion. But the celebration came to a crashing halt when Apple Chief Financial Officer Luca Maestri said in a conference call that the company’s revenue growth would slow in the current quarter due to foreign exchange rates, the semiconductor shortage and tougher comparisons with the previous year.\n“We expect very strong double-digit year-over-year revenue growth during the September quarter,” Maestri said, while continuing to avoid exact revenue guidance due to uncertainty related to the COVID-19 pandemic. “We expect revenue growth to be lower than our June quarter year-over-year growth of 36%.”\nApple’s shares had gained in after-hours trading to that point, but immediately fell back and ultimately ended the extended trading session with a 2% decline.\nBeyond overall revenue, Maestri also warned about one of Apple’s hottest businesses and declined to give any hints about prolonged declines in sales growth.\n“We expect our services growth rate to return to a more typical level,” Maestri said, referring to Apple’s services business, which reached record-high revenue in the quarter by growing 33% to $17.5 billion.\nThat growth rate also benefited from a favorable comparison as certain services were significantly impacted by the very beginning of the COVID-19 lockdowns a year ago, he added.\n“We expect significant growth in services, but not to the level that we’ve seen in June,” he said in response to a question about the company’s guidance.\nWhen asked about the upcoming holiday period, and whether the semiconductor and component shortage would have an impact on what is typically Apple’s biggest quarter, Maestri said he only wanted to talk about one quarter at a time. Some analysts have already been wondering if the second half of this year is going to be as strong as the first half among tech companies, especially the tech giants, and Apple’s June quarter seemed to be reflective of those fears.\nWhile it seems ridiculous to see shares decline after reporting such a mind-blowing quarter — iPhone total revenue alone was nearly $40 billion and Chief Executive Tim Cook said that 5G penetration is still “very very low, and so we feel really good about the future of the iPhone” — concerns that we are at a peak for tech are valid. And as the delta variant continues to create uncertainty about the path of the COVID-19 pandemic, there is even more uncertainty ahead\nAs Cook phrased it Tuesday, “the road to recovery will be a winding one.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":25,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145605049,"gmtCreate":1626219931581,"gmtModify":1703755635892,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"Welcome to the Great roller coaster ride. HAVE YOIR SEAT BELTS BUCKLED TIGHT","listText":"Welcome to the Great roller coaster ride. HAVE YOIR SEAT BELTS BUCKLED TIGHT","text":"Welcome to the Great roller coaster ride. HAVE YOIR SEAT BELTS BUCKLED TIGHT","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/145605049","repostId":"2151560584","repostType":4,"repost":{"id":"2151560584","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626207238,"share":"https://www.laohu8.com/m/news/2151560584?lang=&edition=full","pubTime":"2021-07-14 04:13","market":"us","language":"en","title":"S&P 500 and Nasdaq end down after hitting record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=2151560584","media":"Reuters","summary":"JPMorgan drops amid low interest rates\nU.S. consumer prices surge in June\nBoeing slips on new produc","content":"<ul>\n <li>JPMorgan drops amid low interest rates</li>\n <li>U.S. consumer prices surge in June</li>\n <li>Boeing slips on new production problems for 787 Dreamliners</li>\n <li>Indexes: Dow -0.31%, S&amp;P 500 -0.35%, Nasdaq -0.38%</li>\n</ul>\n<p>(Updates following end of session)</p>\n<p>July 13 (Reuters) - The S&amp;P 500 and Nasdaq ended lower on Tuesday after hitting record highs earlier in the session, with investors digesting a jump in consumer prices in June and earnings from JPMorgan and Goldman Sachs that kicked off the quarterly reporting season.</p>\n<p>The S&amp;P 500 and Nasdaq reached fresh record highs but quickly fell into negative territory after an auction of 30-year Treasuries showed less demand than some investors expected and pushed yields higher.</p>\n<p>Data indicated U.S. consumer prices rose by the most in 13 years last month, while so-called core consumer prices surged 4.5% year over year, the largest rise since November 1991.</p>\n<p>Economists viewed the price surge, driven by travel-rated services and used automobiles, as mostly temporary, aligning with Federal Reserve Chair Jerome Powell's long-standing views.</p>\n<p>\"Any time you get an uptick in interest rates the stock market is going to get nervous, especially on a day like today,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey.</p>\n<p>The S&amp;P 500 growth index dipped 0.05%, while the value index fell 0.70%.</p>\n<p>\"With growth outperforming value, the takeaway is clearly that inflation from a market perspective is not a real threat in the long term,\" said Keith Buchanan, a portfolio manager at GLOBALT Investments in Atlanta, Georgia.</p>\n<p>Ten of the 11 major S&amp;P 500 sector indexes ended lower, with real estate , consumer discretionary and financials each down more than 1%.</p>\n<p>JPMorgan Chase &amp; Co stock fell 1.5% after the company reported blockbuster quarterly profit growth but warned that the sunny outlook would not make for blockbuster revenues in the short term due to low interest rates.</p>\n<p>Goldman Sachs Group Inc dipped 1.2% after its quarterly earnings exceeded forecasts.</p>\n<p>Citigroup , Wells Fargo &amp; Co and Bank of America were due to report their quarterly results early on Wednesday.</p>\n<p>PepsiCo Inc gained 2.3% after raising its full-year earnings forecast, betting on accelerating demand as COVID-19 restrictions continue to ease.</p>\n<p>June-quarter earnings per share for S&amp;P 500 companies are expected to rise 66%, according to Refinitiv data, with investors questioning how long Wall Street's rally would last after a 16% rise in the benchmark index so far this year.</p>\n<p>All eyes now turn to Fed Chair Jerome Powell's congressional testimony on Wednesday and Thursday for his comments about rising price pressures and monetary support going forward.</p>\n<p>The Dow Jones Industrial Average fell 0.31% to end at 34,888.79 points, while the S&amp;P 500 lost 0.35% to 4,369.21.</p>\n<p>The Nasdaq Composite dropped 0.38% to 14,677.65.</p>\n<p>Conagra Brands Inc dropped 5.4% after the packaged foods company warned that higher raw material and ingredient costs would take a bigger bite out of its profit this year than previously estimated.</p>\n<p>Boeing Co fell 4.2% after the Federal Aviation Administration said late on Monday some undelivered 787 Dreamliners have a new manufacturing quality issue.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.85-to-1 ratio; on Nasdaq, a 3.06-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 39 new 52-week highs and no new lows; the Nasdaq Composite recorded 61 new highs and 73 new lows.</p>\n<p>Volume on U.S. exchanges was 9.5 billion shares, compared with the 10.5 billion average for the full session over the last 20 trading days.</p>\n<p>(Additional reporting by Devik Jain and Shreyashi Sanyal in Bengaluru; Editing by Cynthia Osterman)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 and Nasdaq end down after hitting record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 and Nasdaq end down after hitting record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-14 04:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>JPMorgan drops amid low interest rates</li>\n <li>U.S. consumer prices surge in June</li>\n <li>Boeing slips on new production problems for 787 Dreamliners</li>\n <li>Indexes: Dow -0.31%, S&amp;P 500 -0.35%, Nasdaq -0.38%</li>\n</ul>\n<p>(Updates following end of session)</p>\n<p>July 13 (Reuters) - The S&amp;P 500 and Nasdaq ended lower on Tuesday after hitting record highs earlier in the session, with investors digesting a jump in consumer prices in June and earnings from JPMorgan and Goldman Sachs that kicked off the quarterly reporting season.</p>\n<p>The S&amp;P 500 and Nasdaq reached fresh record highs but quickly fell into negative territory after an auction of 30-year Treasuries showed less demand than some investors expected and pushed yields higher.</p>\n<p>Data indicated U.S. consumer prices rose by the most in 13 years last month, while so-called core consumer prices surged 4.5% year over year, the largest rise since November 1991.</p>\n<p>Economists viewed the price surge, driven by travel-rated services and used automobiles, as mostly temporary, aligning with Federal Reserve Chair Jerome Powell's long-standing views.</p>\n<p>\"Any time you get an uptick in interest rates the stock market is going to get nervous, especially on a day like today,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey.</p>\n<p>The S&amp;P 500 growth index dipped 0.05%, while the value index fell 0.70%.</p>\n<p>\"With growth outperforming value, the takeaway is clearly that inflation from a market perspective is not a real threat in the long term,\" said Keith Buchanan, a portfolio manager at GLOBALT Investments in Atlanta, Georgia.</p>\n<p>Ten of the 11 major S&amp;P 500 sector indexes ended lower, with real estate , consumer discretionary and financials each down more than 1%.</p>\n<p>JPMorgan Chase &amp; Co stock fell 1.5% after the company reported blockbuster quarterly profit growth but warned that the sunny outlook would not make for blockbuster revenues in the short term due to low interest rates.</p>\n<p>Goldman Sachs Group Inc dipped 1.2% after its quarterly earnings exceeded forecasts.</p>\n<p>Citigroup , Wells Fargo &amp; Co and Bank of America were due to report their quarterly results early on Wednesday.</p>\n<p>PepsiCo Inc gained 2.3% after raising its full-year earnings forecast, betting on accelerating demand as COVID-19 restrictions continue to ease.</p>\n<p>June-quarter earnings per share for S&amp;P 500 companies are expected to rise 66%, according to Refinitiv data, with investors questioning how long Wall Street's rally would last after a 16% rise in the benchmark index so far this year.</p>\n<p>All eyes now turn to Fed Chair Jerome Powell's congressional testimony on Wednesday and Thursday for his comments about rising price pressures and monetary support going forward.</p>\n<p>The Dow Jones Industrial Average fell 0.31% to end at 34,888.79 points, while the S&amp;P 500 lost 0.35% to 4,369.21.</p>\n<p>The Nasdaq Composite dropped 0.38% to 14,677.65.</p>\n<p>Conagra Brands Inc dropped 5.4% after the packaged foods company warned that higher raw material and ingredient costs would take a bigger bite out of its profit this year than previously estimated.</p>\n<p>Boeing Co fell 4.2% after the Federal Aviation Administration said late on Monday some undelivered 787 Dreamliners have a new manufacturing quality issue.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.85-to-1 ratio; on Nasdaq, a 3.06-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 39 new 52-week highs and no new lows; the Nasdaq Composite recorded 61 new highs and 73 new lows.</p>\n<p>Volume on U.S. exchanges was 9.5 billion shares, compared with the 10.5 billion average for the full session over the last 20 trading days.</p>\n<p>(Additional reporting by Devik Jain and Shreyashi Sanyal in Bengaluru; Editing by Cynthia Osterman)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","UPRO":"三倍做多标普500ETF","IVV":"标普500指数ETF","QLD":"纳指两倍做多ETF",".IXIC":"NASDAQ Composite","SQQQ":"纳指三倍做空ETF","SSO":"两倍做多标普500ETF",".SPX":"S&P 500 Index","SDS":"两倍做空标普500ETF","OEX":"标普100","NDAQ":"纳斯达克OMX交易所","OEF":"标普100指数ETF-iShares","SPXU":"三倍做空标普500ETF",".DJI":"道琼斯","PSQ":"纳指反向ETF","SH":"标普500反向ETF","QID":"纳指两倍做空ETF","SPY":"标普500ETF","TQQQ":"纳指三倍做多ETF","QQQ":"纳指100ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151560584","content_text":"JPMorgan drops amid low interest rates\nU.S. consumer prices surge in June\nBoeing slips on new production problems for 787 Dreamliners\nIndexes: Dow -0.31%, S&P 500 -0.35%, Nasdaq -0.38%\n\n(Updates following end of session)\nJuly 13 (Reuters) - The S&P 500 and Nasdaq ended lower on Tuesday after hitting record highs earlier in the session, with investors digesting a jump in consumer prices in June and earnings from JPMorgan and Goldman Sachs that kicked off the quarterly reporting season.\nThe S&P 500 and Nasdaq reached fresh record highs but quickly fell into negative territory after an auction of 30-year Treasuries showed less demand than some investors expected and pushed yields higher.\nData indicated U.S. consumer prices rose by the most in 13 years last month, while so-called core consumer prices surged 4.5% year over year, the largest rise since November 1991.\nEconomists viewed the price surge, driven by travel-rated services and used automobiles, as mostly temporary, aligning with Federal Reserve Chair Jerome Powell's long-standing views.\n\"Any time you get an uptick in interest rates the stock market is going to get nervous, especially on a day like today,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey.\nThe S&P 500 growth index dipped 0.05%, while the value index fell 0.70%.\n\"With growth outperforming value, the takeaway is clearly that inflation from a market perspective is not a real threat in the long term,\" said Keith Buchanan, a portfolio manager at GLOBALT Investments in Atlanta, Georgia.\nTen of the 11 major S&P 500 sector indexes ended lower, with real estate , consumer discretionary and financials each down more than 1%.\nJPMorgan Chase & Co stock fell 1.5% after the company reported blockbuster quarterly profit growth but warned that the sunny outlook would not make for blockbuster revenues in the short term due to low interest rates.\nGoldman Sachs Group Inc dipped 1.2% after its quarterly earnings exceeded forecasts.\nCitigroup , Wells Fargo & Co and Bank of America were due to report their quarterly results early on Wednesday.\nPepsiCo Inc gained 2.3% after raising its full-year earnings forecast, betting on accelerating demand as COVID-19 restrictions continue to ease.\nJune-quarter earnings per share for S&P 500 companies are expected to rise 66%, according to Refinitiv data, with investors questioning how long Wall Street's rally would last after a 16% rise in the benchmark index so far this year.\nAll eyes now turn to Fed Chair Jerome Powell's congressional testimony on Wednesday and Thursday for his comments about rising price pressures and monetary support going forward.\nThe Dow Jones Industrial Average fell 0.31% to end at 34,888.79 points, while the S&P 500 lost 0.35% to 4,369.21.\nThe Nasdaq Composite dropped 0.38% to 14,677.65.\nConagra Brands Inc dropped 5.4% after the packaged foods company warned that higher raw material and ingredient costs would take a bigger bite out of its profit this year than previously estimated.\nBoeing Co fell 4.2% after the Federal Aviation Administration said late on Monday some undelivered 787 Dreamliners have a new manufacturing quality issue.\nDeclining issues outnumbered advancing ones on the NYSE by a 2.85-to-1 ratio; on Nasdaq, a 3.06-to-1 ratio favored decliners.\nThe S&P 500 posted 39 new 52-week highs and no new lows; the Nasdaq Composite recorded 61 new highs and 73 new lows.\nVolume on U.S. exchanges was 9.5 billion shares, compared with the 10.5 billion average for the full session over the last 20 trading days.\n(Additional reporting by Devik Jain and Shreyashi Sanyal in Bengaluru; Editing by Cynthia Osterman)","news_type":1},"isVote":1,"tweetType":1,"viewCount":28,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885078183,"gmtCreate":1631748783442,"gmtModify":1676530622872,"author":{"id":"3571475992036725","authorId":"3571475992036725","name":"dho","avatar":"https://static.tigerbbs.com/91164006b0a9bd189f1043a2804ae141","crmLevel":3,"crmLevelSwitch":0},"themes":[],"htmlText":"It's not a vaccine!&nbsp;","listText":"It's not a vaccine!&nbsp;","text":"It's not a vaccine!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885078183","repostId":"2167059010","repostType":4,"isVote":1,"tweetType":1,"viewCount":336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}